• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Roche fy2011 9months_results
 

Roche fy2011 9months_results

on

  • 1,024 views

 

Statistics

Views

Total Views
1,024
Views on SlideShare
1,024
Embed Views
0

Actions

Likes
0
Downloads
27
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Roche fy2011 9months_results Roche fy2011 9months_results Presentation Transcript

    • 1
    • RocheNine months YTD 2011 salesCommitted to innovation and profitable growthOctober 13, 2011Basel 2
    • This presentation contains certain forward-looking statements. These forward-lookingstatements may be identified by words such as „believes‟, „expects‟, „anticipates‟, „projects‟,„intends‟, „should‟, „seeks‟, „estimates‟, „future‟ or similar expressions or by discussion of,among other things, strategy, goals, plans or intentions. Various factors may cause actualresults to differ materially in the future from those reflected in forward-looking statementscontained in this presentation, among others:1 pricing and product initiatives of competitors;2 legislative and regulatory developments and economic conditions;3 delay or inability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 litigation;10 loss of key executives or other employees; and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpretedto mean that Roche‟s earnings or earnings per share for this year or any subsequent period willnecessarily match or exceed the historical published earnings or earnings per share of Roche.For marketed products discussed in this presentation, please see full prescribing information on ourwebsite – www.roche.com 3All mentioned trademarks are legally protected
    • Group Severin Schwan Chief Executive Officer 4
    • YTD Sept 2011: Highlights Sales on track for full year guidance • Group and Pharma: low-single digit sales growth 1,2 (+2% & +1%) • Diagnostics: above market sales growth (+6%) Currency impact • Reported sales significantly impacted by strong Swiss franc (-13%p) Outlook confirmed • Core EPS growth target „around 10%‟ 1 Newsflow • US launch of Zelboraf for metastatic melanoma • US filing of vismodegib (hedgehog inh.) for advanced and metastatic BCC • Avastin: CHMP positive recommendation in 1L met. ovarian cancer and mBC approval in Japan 51 at Constant Exchange Rates, 2 excluding Tamiflu
    • YTD Sept 2011: Group salesSupporting full-year guidance, strong currency impact change in % ExcludingCHF bn 2010 2011 CHF CER Tamiflu1 Pharmaceuticals Division 28.4 24.4 -14 -1 +1 Diagnostics Division 7.7 7.1 -8 +6Roche Group 35.3 31.5 -13 0 +2 61 at Constant Exchange Rates, CER (average full year 2010)
    • YTD Sept 2011: Group sales+2%2 sales growth excl. Tamiflu +1% +6% +2% -57% 0% -13% +423 -453 +202 +625 +172 -4,807 -4,635 Pharma Diagnostics Group Tamiflu Group Fx 1 Group Division Division incl. CHF Tamiflu1 avg December 2010 to avg YTD September 11 fx local absolute values at avg 2010 fx 72 CER = Constant Exchange Rates (average full year 2010)
    • Regional performance: Emerging marketsstrongly contribute to sales growth Latin LatinAmerica 16% America 15% All countries in up-swing Asia- Asia 13% Pacific 17% All countries in up-swing North US 1% America 4% Returning to growth Japan -2% Japan 6% Still affected by the earthquake WE -4% Continuing impact of 2010 austerity measures Pharma: Political situation in North Africa CEMAI-6% EMEA 2% and price pressure in Eastern Europe -10% 0% 10% 20% 0% 10% 20% Pharma Diagnostics 8 CER growth rates, excluding Tamiflu
    • Portfolio outlook An update on key compoundsMarketpotentialLarger> CHF 1bnSmaller< CHF 1bn Zelboraf GA101 Vismodegib T-DM1 MetMAb Lebrikizumab Glyt-1 Dalcetrapib Ocrelizumab Pertuzumab Mericitabine Aleglitazar gRED pREDPotentialLaunch 2011 2012 2013 2014 2015 2016Year 9
    • Healthcare reforms and austerity measures1. Policy on receivables strengthened in southern European countries; current exposure to Greece government bond below CHF 50 m2. US – continue to monitor the proposals on budget deficit reduction3. Other countries – as of now, no major negative impact expected Limited impact in 2011 expected / outlook confirmed 10
    • Roche: Supersector leader in Dow JonesSustainability Index – third year in a row Reinforces commitment to creating long-term value for all stakeholders 11
    • Reconfirming increased outlook for 2011Continued strong business performance Sales growth (CER) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market Genentech synergies 2011+ : CHF 1.0 bn* Operational Excellence 2011 : CHF 1.8 bn savings 2012+ : CHF 2.4 bn Core EPS growth target Around 10% (CER) Grow in-line with Core EPS; maintain at least Dividend outlook last year‟s dividend in CHF 12Barring unforeseen events; CER=Constant Exchange Rates; * vs. 2010: CHF 0.8 bn
    • Pharmaceuticals Division Pascal Soriot COO Roche Pharmaceuticals 13
    • YTD Sept 2011: Pharma sales on track to meetguidance 2010 2011 change in % Excluding CHF m CHF m CHF CER Tamiflu1 Pharmaceuticals Division 28,395 24,397 -14 -1 +1 United States 10,878 9,104 -16 +1 +1 Western Europe 7,295 6,210 -15 -4 -4 Japan 3,137 2,712 -14 -6 -2 International 7,085 6,371 -10 +1 +6 Quarterly growth rates 2010 2011 % at CER vs. prior year, excl. Tamiflu Q1 Q2 Q3 Q4 Q1 Q2 Q3 Pharmaceuticals Division +8 +3 +4 +4 +1 +1 0 Roche Pharma (excl. Chugai) +9 +3 +5 +3 +1 +1 +1 Chugai +2 +1 +2 +7 +1 -2 -5 141 at Constant Exchange Rates, CER (average full year 2010)
    • YTD Sept 2011: Pharma sales +1%1 Western Europe Japan United States 26% Pharma sales, -4%1 11% Pharma sales, -2%1 37% Pharma sales, +1%1 • Austerity measures • Disruption of sales activities in Q2/3 • Lucentis, Rituxan, Actemra • Avastin in mBC bottoming out • Biennial price cuts effective April 2010 growing • Actemra: continued uptake • Avastin in mBC bottoming out • Pegasys Q3 +15% Emerging markets/ International 26% Pharma sales, +6%1 • Growth driven by Lat. America and Asia-Pacific 15All growth at Constant Exchange Rates; 1 Excluding Tamiflu
    • Pharma in E7: continuous growth in keyemerging markets CHF m 3000 +11% 2500 +13% Korea +6% +5% 2000 Russia Mexico 1500 Turkey 1000 India 500 China 0 Brazil YTD Sep YTD Sep YTD Sep YTD Sep YTD Sep 2007 2008 2009 2010 2011 16All at FY average 2010 exchange rates; growth at CER, excluding Tamiflu
    • YTD Sept 2011: Pharma Division growth contributorsOncology, Lucentis and Actemra driving growth Herceptin +8% MabThera/Rituxan +7% Lucentis +26%Actemra/RoActemra +86% Pegasys -5% CellCept -12% Boniva/Bonviva -19% US Mircera +45% Western Europe JapanNeorecormon/Epogin -22% International Avastin -8% -600 -400 -200 0 200 400 Tamiflu: -453; -57% 17Absolute amounts in CHF m at 2010 exchange rates
    • Western EuropeImpact of 2010 special effects levelling out 8.8% 2010 2011 Quarterly growth rates EU austerity CER, excl Tamiflu measures Avastin mBC 2.0% impact -0.8% -2.2% -3.6% -4.5% -4.4% Q1 Q2 Q3 Q4 18
    • Solid growth of the oncology franchiseMajor brands local growthCHF bn USA: 1L maintenance in NHL included in new NCCNMabThera/ +7% guidelines; emerging markets driven by uptake in NHL Rituxan indications US & EU: Impact from mBC indication and austerity Avastin -8% measures; good growth in Emerging markets and Japan Improvement in quality and penetration of HER2 testing; Herceptin +8% access initiatives in Emerging markets drive volumes increase Xeloda +6% Strong growth in US and Emerging markets Tarceva +6% Growth in US, Emerging markets and Japan YTD Sept 11 0 1 2 3 4 5 19 Oncology Sept YTD 2011 sales: 14.233 bn
    • Avastin updateOvarian cancer• EU: CHMP positive opinion for 1st line ovarian cancer• US: low likelihood of 1st line ovarian filing (update once OS data available) Breast cancer • mBC approval in Japan • Pending FDA decision on mBC; US mBC patient share bottoming out • AVEREL: in combo with Herceptin, unlikely to meet regulatory requirementsLung cancer• AVAPERL: positive data in combination with pemetrexed in NSCLC Peak sales reconfirmed at CHF 7bn 201 local growth
    • LucentisDriven by growing wet AMD market and new indication US salesCHF m1200 +26%1 • Diabetic Macular Edema (DME): Filed in the US in October 900 • Market share in RVO: 25% in Q3 vs. 24% in Q2 „11 600 • HARBOR study recently unblinded, efficacy data not supporting initiation of further high-dose studies; 0.5 mg PRN 300 dosing to be discussed with FDA 0 YTD 9 YTD 9 YTD 9 YTD 9 08 09 10 111 CER;AMD=wet age-related macular degeneration; DME=diabetic macular edema; RVO=retinal vein occlusion 21Genentech, a member of the Roche Group, retains commercial rights in the US and Novartis has exclusive commercial rights for rest of the world
    • Pegasys Back to growth in US Pegasys US HCV Market trend YTD Sept sales CHF 1.1 bn 7000 6000 • Renewed sales growth in the US in Q3 peginterferon Rx (+15%) after launch of new 5000 direct-acting hepatitis C drugs, with Pegasys as foundation of combinationWeekly Rx 4000 therapies 3000 • Positive momentum for EU expected as Pegasys Rx well 2000 • FDA approval of Pegasys ProClick 1000 DAA disposable auto injector (September) – Launch new dosage form to increase patient 0 convenience Jan Apr Jul Oct Jan Apr Jul „10 „10 „10 „10 „11 „11 „11 Source: IMS NPA Weekly Rx reports 22
    • Actemra/RoActemra in Rheumatoid ArthritisGrowing in all regions Actemra/RoActemra salesCHF m • 24-week ACT RAY X-ray monotherapy500 +86%1 data to be presented at ACR400 • DMARD IR (first-line biologic) filing 2012 in US300 • H2H trial vs Humira (ADACTA): readout H1 2012200 • Subcutaneous formulation: filing 2012 EU, 2013 US; Japanese study positive100 • Did not meet primary end-point in pivotal ankylosing spondylitis trial 0 YTD 9 YTD 9 YTD 9 YTD 9 • sJIA approved in US & EU 08 09 10 11 231 CER
    • 2011: Major clinical news for late-stage NMEsSupporting future growth Compound Indication Study Zelboraf (BRAFi) 1st line met melanoma BRIM3  Lucentis Diabetic macular edema RIDE  RISE Phase III Avastin Relapsed ovarian cancer OCEANS  pertuzumab + Herceptin 1st line HER2+ mBC CLEOPATRA  Herceptin Early HER2+BC sc HANNAH vismodegib (Hedgehog i) Advanced BCC Pivotal study, ERIVANCE  T-DM1 1st line HER2+ mBC PFS data  GA101 Relapsed indolent NHL GAUSS H2H against MabThera/RituxanPhase II MetMAb NSCLC 2nd / 3rd line Final data  lebrikizumab Severe uncontrolled asthma MILLY MOLLY mericitabine Hepatitis C PROPEL final data; JUMP-C dalcetrapib CV risk reduction dal-VESSEL  dal-PLAQUE  24
    • Significant news-flow in Q3 2011Approvals / • Zelboraf in US, metastatic melanomaPositive opinions • Tarceva in EU, 1L EGFR mutated NSCLC • Avastin in front-line ovarian cancer; positive CHMP opinionFilings • Lucentis in US (October), Diabetic Macular Edema (DME) • Avastin in EU, recurrent ovarian cancer • vismodegib (hedgehog inh) in US, advanced/met BCCData presented • T-DM1 vs. Herceptin 1st line HER2+ mBC ph II • Zelboraf updated OS from BRIM3 and ph I • lebrikizumab MILLY ph II proof of concept • dalcetrapib dal-PLAQUE and dal-VESSEL ph II 25
    • ZelborafUS approval and launch in record time 2006 2007 2008 2009 2010 2011 IND Phase I results + BRIM2 results BRIM3 results US launch Less than 5 years from IND to first launch • Fastest development program • Fastest approval in Roche portfolio (<5 years from IND to FDA approval) (3.5 months after submission) • Fastest initiation of a global Expanded • Five days from approval to launch Access Program • 5 weeks after launch: sales of CHF 11 m 26
    • T-DM1 vs. Herceptin + docetaxel in breast cancer Potential for efficacy with lower rate of chemo-related side effects PFS, 1st line HER2+ breast cancer 1.0 Median Hazard Log-rank PFS, mos ratio P value Phase II 0.8 T+D 9.2 0.594 0.0353 EMCC/ESMO 2011 Proportion progression-free T-DM1 14.2 0.6 • significant improvement in PFS 0.4 Trastuzumab • markedly lower rate of 0.2 + docetaxel (n=70) grade ≥3 AEs T-DM1 (n=67) (46.4% vs 89.4%) 0.0 0 2 4 6 8 10 12 14 16 18 20Number of patients at risk Time (months)T+D 70 66 63 53 43 27 12 4 2 2 0T-DM1 67 60 51 46 42 35 22 15 6 3 0 Filing of T-DM1 in 2nd line HER2+ breast cancer (EMILIA study) in 2012 Hurvitz SA, et al. Abstract 5.001. ESMO 2011 27
    • Short-term newsflowPipeline progress Pertuzumab in 1L HER2+ breast cancer pivotal phase III CLEOPATRA SABCS (December 6-10, San Antonio) Subcutaneous Herceptin in early HER2+ BC pivotal phase III HANNAH top-line data in Q4 2011 GA101 vs. MabThera/Rituxan in indolent non-Hodgkin’s lymphoma phase II GAUSS ASH (December 10-13, San Diego) Roche Late-Stage Pipeline Update Focus on data presented at ESMO and ERS London, November 7th, 2011 28
    • Diagnostics Division Daniel O’Day COO Roche Diagnostics 29
    • YTD Sept 2011: Diagnostics Division salesContinued solid growth above the market 2010 2011 CHF CER CHF m CHF m growth growth Professional Diagnostics 3,602 3,430 -5% 9% Diabetes Care 2,191 1,938 -12% 1% Molecular Diagnostics 900 801 -11% 3% Applied Science 646 544 -16% -2% Tissue Diagnostics 393 382 -3% 15% Diagnostics Division 7,732 7,095 -8% 6%CER = Constant Exchange Rates (average full year 2010) 30
    • YTD Sept 2011: Sales driven by Asia-Pacific,EMEA and North-America Europe, Middle East, Africa North America 50% Dia sales, +2% Japan 25% Dia sales, +4% • Immunoassays and Coagulation 5% Dia sales, +6% monitoring driving growth • Immunoassays +17% • 12% growth in Professional • Impacted by reduced blood screening • Molecular diagnostics +8% Diagnostics • Molecular Diagnostics flat Asia Pacific Latin America 13% Dia sales, +17% 7% Dia sales, +15% • Professional Diagnostics +21% • Growing strongly in all Business Areas • Molecular Diagnostics up +16% (primarily blood screening) • Professional Diagnostics +17% • China +25% growthAll growth in Constant Exchange Rates (average full year 2010) 31
    • Growth driven by Professional Diagnostics andTissue DiagnosticsCHF bn YTD Sept ‘11 vs. YTD Sept ‘10 CER growthProfessional Strong growth in Nth America (9%), Latin America +9% Dia (17%) and Asia Pacific (21%); Driven by Immunoassays Diabetes Maltose independent Accu-Chek Aviva Plus strips +1% Care approved in US Molecular +3% cobas BRAF test launched US & EU; Won Swedish tender Dia for pilot primary screening cervical cancer with HPV test Applied Continued impact from deceased H1N1 testing; -2% Science Flat global research funding EMEA North America Launched 11 new Abs incl. H. pylori, BCL-2 and MLH-1; Tissue Dia +15% RoW Completed acquisition of mtm labs (cervical cancer) 0 1 2 3 4CER = Constant Exchange Rates (average full year 2010) 32EMEA = Europe, Middle East, Africa
    • YTD Sept 2011: Professional DiagnosticsStrong growth driven by immunoassays CHF 3.4 bn, +9% CER growth • Solid instrument placements other Immunoassays • Continuous growth in Immunoassays (+13%) and Clinical Chemistry POCproducts • Continued roll-out of Vitamin D Total (+7%) test in EU and ROW • POC Coagulation monitoring (+14%) – proven medical value of testing – superior product in CoaguChek Clinical – strong growth in EMEA and Nth Chemistry America (+6%)CER = Constant Exchange Rates (average full year 2010) 33EMEA = Europe, Middle East, Africa
    • Roche awarded first public tender for primaryscreening for cervical cancer with cobas HPV test • Karolinska University Hospital in Sweden to screen women for cervical cancer with cobas HPV test • Represents first primary screening pilot program to be implemented in Europe Fully automated throughput up to 388/12hr • Results and publications to aid in evaluation for country wide implementation • First significant step towards replacing pap smear in a stringent program Hi Risk GT 16 GT 18 Control 1 2 3 4 • In EU, 109 million women in target age group for Genotypes 16/18 & 12 high-risk HPV in one test cervical cancer screening** Second edition of the European Guidelines for Quality Assurance of Cervical Cancer Screening, 2008 34
    • Personalised healthcare becoming realityCommercialisation of cobas BRAF test in US and EU • Joint US launch of Zelboraf and cobas BRAF test Approved in US for people with BRAF • Roche Pharma sales force direct V600E mutated metastatic melanoma oncologists to labs offering cobas BRAF cobas BRAF test • Only FDA approved companion diagnostic for Zelboraf • Good initial market uptake with key cobas BRAF test labs• Identifies patients with BRAF V600E mutations• Detects patients missed by sequencing• Provides consistent and reliable results 35BRAF gene mutations detected in ~8% of all cancers, over 50% of malignant melanomas
    • Key launches for 2011* • Vitamin D total and HE4 immunoassays (EU) Professional Diagnostics • cobas 8000 modular analyzer series, cobas c 702 module (EU US ) • cobas b 123 POC system for bloodgas & electrolytes (US) • Accu-Chek Mobile LCM (EU) • Accu-Chek Combo (US)Diabetes Care • Accu-Chek Nano (US) • Accu-Chek Aviva Plus MI strip (US)  • cobas 4800 HPV Test (US)  • cobas 4800 EGFR Mutation Test (EU)Molecular Diagnostics • cobas 4800 KRAS Mutation Test (EU)  • cobas 4800 BRAF V600 Mutation Test (EU, US)  • HLA genotyping on GS Junior & FLX sequencing systems (global)  • GS FLX Titanum-XL system (global) Applied Science • Ultra-high resolution CGH arrays (global) • LightCycler Nano for real time PCR analysis (global)  • ER/PR antibody for IHC (US)Tissue Diagnostics • HER2 dual colour ISH probe (US)  • OptiView detection system (US, EU)  Diagnostics Division Outlook: sales growth significantly above the market 36* Subject to appropriate regulatory approvals barring unforeseen events
    • Group Alan Hippe Chief Financial Officer 37
    • Highlights• Further balance sheet deleverage: tender offer for the March 2012 CHF bond, P&L impact up to CHF -10 m• Credit rating: Moody‟s upgrade of Roche from A2 to A1- stable outlook• Carefully monitor receivables, particularly in Mediterranean countries• On track to deliver Operational Excellence savings and profit targets 38
    • Exchange rate impact on sales growth Negative impact, in particular from USD and EUR Oth Local USD EUR Europe As-Pac Lat-Am JPY Other CHF CER sales 0.4% growthYTD 9 2011 vs.YTD 9 2010 -6.4% CHF sales growth YTD 9 2011 -12.8% vs. -2.9% YTD 9 2010 -1.1% -0.9% -0.9% -0.8% -0.2% CER = Constant Exchange Rates (average full year 2010) 39
    • Currency impact on Swiss Franc results CHF/USD average YTD 2010 1.07 1.04 -18% Average YTD 2011 0.88 Assuming the 30 September 2011 exchange 0.96 0.95 rates remain stable until year-end, FY 2011 0.92 0.90 0.87 0.84 0.82 0.87 0.90 0.90 Fx Rate at 0.90 impact is expected to be (%) Monthly average fx rate 2011 0.78 30 Sep 2011 J F M A M J J A S O N D FY Sales -12 CHF/EUR Core operating -15 average YTD 2010 1.40 profit 1.38 Average YTD 2011 -12% Core EPS -14 1.241.28 1.30 1.29 1.30 1.25 1.21 1.22 1.22 1.22 1.18 1.20 1.12 J F M A M J J A S O N D 40
    • Roche with relatively strong credit rating despite high debt levelS&P rating AAA J&J Moody’s upgrade of Roche AA+ Merck Pfizer Abbott from A2 to A1- stable outlook AA Takeda BD Roche AA- AZ Sanofi Novartis • “reflects Roches solid Amgen Lilly deleveraging after its A+ GSK A BMS acquisition of Genentech in A- March 2009” Gilead Bayer BBB+ Biogen • “benign exposure to patent BBB expiries” BBB- BB+ • “relatively high visibility of future cash flows” -35 -30 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 35 2010 Leverage1 (%) 1Net Debt / Total Assets (%) 41 Source: Thompson Datastream; Bloomberg (May 23; 2011); BCG analysis
    • Reconfirming increased outlook for 2011Continued strong business performance Sales growth (CER) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market Genentech synergies 2011+ : CHF 1.0 bn* Operational Excellence 2011 : CHF 1.8 bn savings 2012+ : CHF 2.4 bn Core EPS growth target Around 10% (CER) Grow in-line with Core EPS; maintain at least Dividend outlook last year‟s dividend in CHF 42Barring unforeseen events; CER=Constant Exchange Rates; * vs. 2010: CHF 0.8 bn
    • 43
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group YTD Sept 2011 resultsDiagnosticsForeign exchange rate information 44
    • Roche Development PipelineProjects in Phase 1 phase I (44 NMEs) Phase I Projects - oncology Phase I Projects – other DTAs RG7112 MDM2 ant (2) solid & hem tumors RG4934 anti-IL-17 MAb RA RG7167 CIF/MEK inh solid tumors RG7185 CRTH2 antag asthma RG7212 Tweak MAb oncology CHU Anti-IL 6 MAb RA RG7256 BRaf inh(2) BRAF mut. melanoma RG7432 nucleoside pol inh HCV RG7304 Raf & MEK dual inh solid tumors RG7236 Cat S antag CV risk in CKD RG7321 PI3 kinase inh solid tumors RG7273 ABCA1 inducer dyslipidemia RG7334 anti-PLGF MAb solid tumors RG7652 - metabolic RG7356 anti-CD44-MAb solid tumors RG7685 GIP/GLP-1 dual ago type 2 diabetes RG7420 MEK inh solid tumors RG7421 MEK inh solid tumors RG1578 mGluR2 antag (2) depression RG7422 PI3 K/mTOR inh solid & hem tumors RG1662 GABRA5 cogn. disorders RG7440 AKT inhibitor solid tumors RG7314 V1 receptor antag (2) autism RG7444 anti-FGFR3 MAb oncology RG7129 BACE inh Alzheimer‟s RG7446 tumor immunotherapy oncology RG7166 triple reuptake inh depression RG7450 - ADC prostate ca. RG7458 - ADC ovarian ca. RG7459 IAP ant (2) solid tum & lymphoma RG7593 anti-D22 ADC hem. malignancies RG7594 anti-angiogenic solid tumors NME Additional Indication RG7596 - ADC hematologic tumors RG7597 anti-Her3/EGFR m. epithelial tumors Oncology RG7598 - ADC multiple myeloma Inflammation/Immunology RG7599 - ADC oncology Virology RG7601 Bcl-2 inh CLL Metabolic/Cardiovascular RG7602 Chk-1 inh tumors or lymphoma CNS Ophthalmology RG7603 - solid tumors or NHL Others RG7604 PI3K inh oncology RG7686 anti-glypican-3 MAb liver cancer RG-No Roche Genentech managed CHU Chugai managed CHU ALK inhibitor NSCLC CHU - solid tumors CHU WT-1 vaccine oncology 45Status as of September 30, 2011
    • Roche Development PipelineProjects in Ph 2, 3 and Registration phase II phase III Registration (19 NMEs + 7 Als) (8 NMEs + 28 Als) (2 NMEs + 6 Als) RG1273 pertuzumab HER2+ EBC RG105 Rituxan NHL fast infusion RG4351 Avastin ovarian cancer 1st line RG1273 pertuzumab HER2+ mBC 2nd line RG105 MabThera NHL s.c. formulation RG4352 Avastin relapsed ovarian ca RG3502 T-DM1 HER2+ EBC RG435 Avastin HER2+ BC adj RG14153 Tarceva NSCLC EGFR mut 1st line RG3616 vismodegib operable BCC RG435 Avastin BC combo Herceptin 1st line RG36164 vismodegib advanced BCC RG3638 MetMAb mNSCLC RG435 Avastin NSCLC adj RG36264 Activase extended time window AIS RG3638 MetMAb mBC RG435 Avastin HER2-neg. BC adj RG36454 Lucentis diabetic macular edema RG3638 MetMAb mCRC 1L RG435 Avastin triple-neg. BC adj RG72045 Zelboraf metastatic melanoma RG7160 EGFR Mab solid tumors RG435 Avastin high risk carcinoid CHU EPOCH chemo induced anemia RG7204 Zelboraf papillary thyroid cancer RG435 Avastin glioblastoma 1st line RG7433 navitoclax (ABT-263) sol & hem tum RG435 Avastin mCRC TML 1 CHMP positive opinion EU RG7414 anti-EGFL7 MAb solid tumors RG435 Avastin mBC 2nd line 2 submitted in the EU RG597 Herceptin HER2+ BC s.c. form. 3 approved in the EU RG3637 lebrikizumab severe asthma 4 submitted in the US RG597 Herceptin HER2+ adj BC (2yrs) RG7413 rhu Mab Beta7 ulcerative colitis 5 approved in the US RG1273 pertuzumab HER2+ mBC 1st line RG7415 rontalizumab SLE RG1415 Tarceva NSCLC adj RG7416 anti-LT alpha MAb RA RG1415 Tarceva NSCLC EGFR mut 1st line RG7449 anti-M1 prime MAb asthma RG3502 T-DM1 HER2+ adv. mBC RG7128 mericitabine HCV NME RG3502 T-DM1 HER2+ mBC 3rd l. RG7227 danoprevir HCV Additional Indication RG3502 T-DM1 HER2+ mBC 1st l. RG4929 11 beta HSD inh metabolic diseases RG7159 GA101 CLL RG1512 P selectin MAb ACS/CVD Oncology RG7159 GA101 iNHL relapsed RG7418 anti-oxLDL MAb sec prev CV events Inflammation/Immunology RG7159 GA101 DLBCL Virology RG1450 gantenerumab Alzheimer‘s RG7159 GA101 iNHL front-line Metabolic/Cardiovascular RG1577 MAO-B inh AD CNS RG105 MabThera ANCA assoc vascul RG7090 mGluR5 antag (2) TRD Ophthalmology RG1569 Actemra sc formulation RA RG7412 anti-Abeta MAb Alzheimer‘s Others RG1569 Actemra early RA RG7417 anti-factor D Fab geographic atrophy RG1569 Actemra RA DMARD IR H2H RG-No Roche Genentech managed RG3648 Xolair chronic idiopathic urticaria CHU Chugai managed RG105 MabThera is branded as RG1439 aleglitazar CV risk reduction in T2D Rituxan in US and Japan RG1658 dalcetrapib atherosc. CV risk red. RG1569 Actemra is branded as CHU tofogliflozin (SGLT2) type 2 diabetes RoActemra in EU RG1594 ocrelizumab RMS RG1594 ocrelizumab PPMS RG1678 GRI schizophrenia negative sympt. RG1678 GRI schizophrenia subopt control 46 Status as of September 30, 2011 RG3645 Lucentis AMD high dose
    • Changes to the development pipeline Since H1 2011 update New to Phase I New to Phase II New to Phase III New to RegistrationNew NMEs transitioned from Ph0 New NME in Ph2 following FPI New in Ph3 following FPI New NME Filed(5NMEs) RG7413 MAb Beta7 ulcerative colitis RG1594 ocrelizumab RMS RG3616 vismodegib advanced BCCRG7212 Tweak MAb oncology (US)RG7314 V1 receptor antag (2) New NME in Ph2 following in- New AI in Ph3 folllowing FPIautism licensing from Evotec RG3502 T-DM1 HER2+ mBC 3rd New AIs FiledRG7129 BACE inh Alzheimer‟s RG1577 MAO-B inh in AD line RG435 Avastin relapsed ovarianRG7598 oncology cancer (EU)RG7652 metabolic New AI in Ph2 following FPI RG3626 Activase extended time RG3638 MetMAb mCRC 1L window (US)New NMEs managed by Chugai RG3645 Lucentis diabetic macularCHU WT-1 cancer vaccine edema (US)CHU anti-IL6 MAb in RA Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration NME from Chugai Discontinuation (1AI) Approved in EU CHU Topoisomerase inh in gastric RG1569 Actemra ankylosing RG105 Actemra sJIA cancer spondylitis 47 NME = new molecular entity; AI = additional indication; FPI = first patient in
    • Projected NME Submissions and their rontalizumab (RG7415) SLE anti-LT alpha Mab (RG7416) rheumatoid arthritisAdditional Indications Mab Beta7 (RG7413) ulcerative colitis lebrikizumab (RG3637) asthmaProjects Currently in Phase 2 and 3 anti-EGFL7 Mab (RG7414) solid tumors anti-M1 prime Mab (RG7449) asthma EGFR Mab (RG7160) aleglitazar (RG1439) solid tumors CV risk reduction in T2D GA101 (RG7159) P selectin huMab (RG1512) DLBCL CVD GA101 (RG7159) Anti-oxLDL (RG7418) NHL indolent frontline prevent secondary CV GA101 (RG7159) 11 beta HSD (RG4929) NHL refractory metabolic diseases MetMAb (RG3638) gantenerumab (RG1450) mNSCLC, mBC, mCRC Alzheimer’s disease T-DM1 (RG3502) navitoclax MAOB inh (RG1577) ABT-263 (RG7433) HER2+ mBC 1st line solid & hem tumors Alzheimer’s disease Zelboraf (RG7204) met. melanoma  GA101 (RG7159) CLL mericitabine (RG7128) HCV pertuzumab (RG1273) HER2+ EBC mGluR5 antag (2) (RG7090) Txt resistant depression pertuzumab (RG1273) dalcetrapib (RG1658) * danoprevir RG7227) vismodegib (RG3616) anti-abeta Mab (RG7412) HER2+ mBC1st line atherosclerosis CV risk red. (HCV protease inh) operable basal cell ca Alzheimer’s disease vismodegib (RG3616) adv basal cell ca (US)§  T-DM1 (RG3502) HER 2+ advanced mBC glycine reuptake inhib. (RG1678) schizophrenia# ocrelizumab (RG1594) PPMS and RMS Zelboraf (RG7204) Papillary thyroid ca anti-factor D Fab (RG7417) geographic atrophy 2011 2012 2013 2014 Post 2014Unless stated otherwise, submissions are planned to occur in US and EU. indicates a submission which has occurred with regulatory action pending Oncology CNS Inflammation/Immunology Ophthalmology* NDA timeline is driven by the event rate in dal-OUTCOMES; updated timeline estimate will Virology NMEbe provided in Q3 2012 after 2nd year event rate is known Metabolic/Cardiovascular# negative symptoms and sub-optimal control§ Filing timelines in EU subject to discussion with EMA 48 Status as of September 30, 2011
    • Projected additional indications submissions of existing products Projects currently in Phase 2 and 3 Avastin relapsed ovarian cancer (US) Avastin mBC 2nd line (EU) Avastin mCRC TML Herceptin Avastin sc formulation HER2+ HER2+ BC adj Avastin + Herceptin Avastin HER2+ mBC 1st line triple negative BC adj MabThera Avastin sc formulation (EU) glioblastoma 1st line Rituxan Tarceva (US) Herceptin NHL faster infusion (US) NSCLC EGFR mutation 1st line HER2+ BC adj 2 year Avastin Actemra Tarceva ovarian cancer 1st line (US) DMARD IR (US) NSCLC adj (EU) Avastin  relapsed ovarian cancer (EU) Actemra RA DMARD H2H (EU) Xolair (US) chronic idiopathic urticaria Activase extended time window AIS (US) Actemra sc formulation (EU) Actemra early RA Avastin HER2- BC adj Lucentis  diabetic macular edema (US) Lucentis AMD 0.5 mg PRN (US) Actemra sc formulation (US) Tarceva NSCLC adj (US) Avastin NSCLC adj 2011 2012 2013 2014 Post 2014Unless stated otherwise, submissions are planned to occur in US and EU. Oncology CNS Inflammation/Immunology Ophthalmology Virology Metabolic/Cardiovascular 49Status as of September 30, 2011
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group Q3 2011 salesDiagnosticsForeign exchange rate information 50
    • AvastinOvarian cancer clinical development programmePatient Front-line metastatic Relapsed platinum-sensitivepopulation ovarian cancer ovarian cancer Phase III Phase III Phase IIIPhase/study GOG-0218 ICON7 OCEANS# of patients N=1,873 N=1,528 N=484Design • ARM A: Paclitaxel and carboplatin for 6 cycles plus • ARM A: Paclitaxel and carboplatin for • ARM A: Carboplatin, gemcitabine, and 5 cycles of concurrent placebo followed by placebo 6 cycles concurrent placebo for 6 cycles, followed by alone for up to 22 cycles (15 months) • ARM B: Paclitaxel and carboplatin placebo alone until disease progression • ARM B: Paclitaxel and carboplatin for 6 cycles plus plus concurrent Avastin for 6 cycles • ARM B: Carboplatin, gemcitabine, and 5 cycles of concurrent Avastin followed by placebo followed by Avastin alone for up to 18 concurrent Avastin for 6 cycles, followed by alone for up to 22 cycles (15 months) cycles (12 months) Avastin alone until disease progression. • ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months)Avastin dose • 15 mg/kg q3 weeks • 7.5 mg/kg q3 weeks • 15 mg/kg q3 weeksPrimary • Progression-free survival • Progression-free survival • Progression-free survivalendpointStatus • Study met its primary endpoint in Q1 2010 • Study met its primary endpoint Q3 • Study met its primary endpoint Q1 2011 • Data presented at ASCO 2010 and 2011 2010 • Data presented at ASCO 2011 • Data presented at ESMO 2010 and ASCO 2011 • EMA submission Q4 2010, positive CHMP opinion Q3’11 • EMA submission Q3 2011 • FDA submission in Q4 2011 only if clear benefit is seen on overall • FDA submission in Q1’12 (with more mature survival endpoint overall survival data) 51ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology.
    • AvastinBreast cancer development programmePatient First-line HER2-negative Second-line HER2-negative First-line HER2-positivepopulation Phase III Phase III Phase III Phase IIIPhase/study RIBBON-1 AVADO RIBBON-2 AVEREL# of patients N=1,238 N=736 N=684 N=424Design • ARM A: Anthracycline or • ARM A: Placebo plus • ARM A: Chemotherapy • ARM A: Docetaxel plus taxane plus Avastin OR docetaxel (taxane, Xeloda, gemcitabine, Herceptin Xeloda plus Avastin • ARM B: 7.5 mg/kg dose of or vinorelbine) plus Avastin • ARM B: Docetaxel plus • ARM B: Anthracycline or Avastin plus docetaxel • ARM B: Chemotherapy plus Herceptin plus Avastin taxane plus placebo OR • ARM C: 15 mg/kg dose of placebo Xeloda plus placebo Avastin plus docetaxelAvastin dose • 10 mg/kg q2 weeks or 15 • 15 mg/kg or 7.5 mg/kg q3 • 15 mg/kg q3 weeks • 15 mg/kg q3 weeks mg/kg q3 wks weeksPrimary • Progression-free survival • Progression-free survival • Progression-free survival • Progression-free survivalendpoint (PFS)Status • EU label extended to include • EU: Docetaxel removed from • EU – Consider filing with • Study did not meet protocol Xeloda (June 2) label after EC decision mature OS data in 2012 specified primary endpoint • US: FDA - Received Complete • US: Received Complete • FDA - Received Complete • Improvement in PFS Response Letter Q4 2010 Response Letter Q4 2010 Response Letter Q4 2010 (Investigator assessed) did not • ROW: Approved in 20+ reach significance countries incl. CH • Improvement in PFS (IRC assessed) was statistically significant but is unlikely to meet regulatory approval requirements • No new safety signals 52
    • AvastinClinical development programmes in other tumor types Patient Metastatic colorectal cancer High risk carcinoid Newly diagnosed glioblastoma population Phase III Phase III Phase III Phase/study ML18147 SWOG SO518 AVAglio TML # of patients N=810 N=424 N=920 Design • 1st-line treatment with • ARM A: Depot octreotide plus • ARM A: Concurrent radiation and chemotherapy* plus Avastin interferon alpha temozolomide plus placebo; • Once patients progress, they are • ARM B: Depot octreotide plus followed by maintenance TMZ randomised to: Avastin plus placebo for 6 cycles; then • ARM A: Chemotherapy* alone placebo until disease progression • ARM B: Chemotherapy* + • ARM B: Concurrent radiation and Avastin TMZ plus Avastin; followed by maintenance TMZ plus Avastin for * Physician‟s choice 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression Avastin • 5 mg/kg q2 weeks or • 15 mg/kg q3 weeks • 10 mg/kg q2 weeks or 15 mg/kg dose 7.5 mg/kg q3 weeks q3 weeks Primary • Overall survival • Progression-free survival • Progression-free survival endpoint • Overall survival Status • Enrolment completed Q2 2010 • FPI Q1 2008 • FPI Q2 2009 • Expect data Q1 2012 • Expect data 2013 • Enrolment completed Q1 2011 • Expect data 2012 53
    • AvastinAdjuvant clinical development programmePatient Adjuvant Adjuvantpopulation lung cancer breast cancer Phase III Phase III Phase III Phase IIIPhase/study ECOG 5103 BEATRICE BETH ECOG 1505 HER2-negative Triple-negative HER2-positive# of patients N=1,500 N=4,950 N=2,530 N=3,600Design • ARM A: Cisplatin plus • ARM A: Anthracycline plus • ARM A: Anthracycline ± • COHORT 1: Docetaxel/ vinorelbine, docetaxel, cyclophosphamide (AC) taxane or taxane-based carboplatin plus Herceptin ± gemcitabine or pemetrexed followed by paclitaxel chemo alone Avastin • ARM B: Cisplatin plus • ARM B: AC plus Avastin • ARM B: Anthracycline ± • COHORT 2: Docetaxel plus vinorelbine, docetaxel, followed by paclitaxel plus taxane or taxane-based Herceptin ± Avastin, followed gemcitabine or pemetrexed Avastin chemo plus Avastin for 1 year by 5-Fluorouracil, Epirubicin, plus Avastin up to 12 months • ARM C: AC plus Avastin Cyclophosphamide followed by paclitaxel plus Avastin, followed by Avastin For both cohorts, patients up to 12 months receive Herceptin ± Avastin to complete one year of targeted therapyAvastin dose • 15 mg/kg q3 weeks • 15 mg/kg q3 weeks • Dosing equivalent to 5 • 15 mg/kg q3 weeks mg/kg/wPrimary • Overall survival • Disease-free survival • Disease-free survival • Disease-free survivalendpointStatus • FPI Q3 2007 • FPI Q4 2007 • FPI Q4 2007 • FPI Q2 2008 • Recruitment ongoing • Enrolment completed Q2‟11 • Enrolment completed Q4 2009 • Enrolment completed Q4 2010 • Expect data 2014 • Expect data 2012 • Expect data 2013 54
    • HerceptinThe standard of care for HER2+ early breast cancer Patient Adjuvant HER2-positive Early-stage HER2-positive population breast cancer breast cancer Phase III Phase III Phase/study HERA HANNAH # of patients N=5,102 N=595 Design • ARM A: Herceptin for 12 months • ARM A: Chemotherapy* concurrent with • ARM B: Herceptin for 24 months Herceptin subcutaneous for every three • ARM C: Observation weeks for the first 8 cycles • ARM B: Chemotherapy* concurrent with Herceptin intravenous for every three weeks for the first 8 cycles *Chemotherapy = docetaxel then 5-FU, epirubicin, and cyclophosphamide Primary • Disease-free survival • Serum concentration endpoint • Pathologic complete response Status • Final 2-year versus 1-year analysis • FPI Q4 2009 expected in 2012; event-driven • Enrolment completed Q4 2010 • Expect data October of 2011Subcutaneous Herceptin : applies Enhanze technology, partnered with Halozyme 55
    • MabThera/RituxanDevelopment programmes Oncology Immunology Front-line diffuse large B-cell or Patient Front-line follicular non- follicular non-Hodgkin’s ANCA-associated vasculitis population Hodgkin’s lymphoma lymphoma Phase III Phase IIIb Phase II/III Phase/study Subcutaneous study RATE* RAVE* Study being conducted ex-US Faster infusion study # of patients N=405 N=450 N=197 Design • ARM A: Intravenous MabThera • Prospective, open-label, single arm • Non-inferiority efficacy and safety plus chemotherapy (CHOP or study study of MabThera/Rituxan and CVP) glucocorticoids versus • ARM B: Subcutaneous MabThera conventional therapy plus chemotherapy (CHOP or (cyclophosphamide) CVP) • Responders will continue on maintenance every 8 weeks over 24 months Primary • Pharmacokinetics, safety and • To determine the incidence of • Induction of complete remission at endpoint efficacy Grade 3 or 4 infusion-related 6 months, defined as a BVAS/WG toxicities resulting from faster of 0 and off glucocorticoid therapy infusion of MabThera/Rituxan Status • FPI Q1 2011 • FPI Q3 2008 • Data presented at ACR 2009 • Expect data 2012 • Enrolment completed Q4 2010 • FDA approved use of Rituxan in • Expect data H2 2011 WG and MPA in Q2 2011*In collaboration with Biogen Idec; subcutaneous MabThera: applies Enhanze technology, partnered with HalozymeCHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; CVP = Cyclophosphamide, Vincristine and Prednisolone. 56WG - Wegeners Granulomatosis, MPA - Microscopic Polyangiitis
    • TarcevaNew approaches to treating lung cancer First-line metastatic Patient Adjuvant non-small non-small cell lung cancer population cell lung cancer EGFR mutation-positive* Phase III Phase III Phase/study RADIANT EURTAC N=974 # of patients N=174 (2:1 randomisation) Design • Following surgical resection ± adjuvant • ARM A: Tarceva chemotherapy: • ARM B: Chemotherapy (platinum-based • ARM A: Tarceva up to 2 years doublet) • ARM B: Placebo up to 2 years Primary • Disease-free survival • Progression-free survival endpoint • EGFR IHC and/or FISH-positive Status • Enrolment completed Q3 2010 • Study met its primary endpoint Q1 2011 • Expect final results in 2012 • Data presented at ASCO 2011 • Expect FDA sNDA submission in 2012 • EU granted approval in Q3 2011In collaboration with OSI Pharmaceuticals, now part of Astellas group;Tarceva is a trademark of OSI Pharmaceuticals, LLC 57
    • Actemra/RoActemraInterleukin 6 receptor inhibitor• Rheumatoid arthritis programme Rheumatoid arthritisPatient Early moderate-to-severe Moderate-to-severe Moderate-to-severe DMARD inadequatepopulation rheumatoid arthritis rheumatoid arthritis rheumatoid arthritis responders Phase III Phase III Phase III Phase IIIPhase/study ADACTA SUMMACTA BREVACTA FUNCTION Head-to-head study Subcutaneous study Subcutaneous study# of patients N=1,128 N=300 N=1,200 N=600Design • ARM A: Actemra 8 mg/kg • ARM A: Actemra • Add-on to DMARD therapy • Add-on to DMARD therapy • ARM B: Actemra 8 mg/kg • ARM B: Humira • Weekly dosing • Dosing every two weeks plus MTX • ARM A: Subcutaneous • ARM A: Subcutaneous • ARM C: Actemra 4 mg/kg Actemra plus intravenous Actemra plus MTX placebo • ARM B: Subcutaneous • ARM D: MTX alone • ARM B: Intravenous Actemra placebo plus subcutaneous placeboPrimary • DAS28 remission at 24 weeks, • DAS28 at 24 weeks • ACR 20 at week 24 • ACR 20 at week 24endpoint 1 year and 2 yearsStatus • FPI Q4 2009 • FPI Q2 2010 • FPI Q3 2010 • FPI Q1 2011 • Recruitment completed Q2 • Expect data H1 2012 • Recruitment completed Q3 2011 2011 • Expect data 2012 • Expect data 2012In collaboration with ChugaiMTX = Methotrexate; DMARD = Disease-Modifying Anti-Rheumatic Drugs. 58Humira® (adalimumab) is a registered trademark of Abbott Laboratories.
    • LucentisFor the treatment of age-related macular degenerationand macular edema following retinal vein occlusion Patient Neovascular (wet) age-related Diabetic macular edema population macular degeneration Phase III Phase III Phase III Phase/study HARBOR RIDE RISE High dose study # of patients N=1,110 N=382 N=378 Design • Randomised double-masked study • Randomised, sham-controlled study of monthly intravitreal injections of 0.5 comparing efficacy and safety of and 0.3 mg Lucentis for a total of 36 injections in patients with clinically intravitreal injections of 0.5 mg and significant macular edema with center involvement secondary to diabetes 2.0 mg Lucentis administered mellitus (Type I or Type II). monthly or PRN in patients with wet AMD Primary • Mean change in best corrected • Proportion of patients who gain ≥ 15 letters in BCVA score compared to endpoint visual acuity (BCVA) compared to baseline after 24 monthly injections (secondary endpoints include 36 month baseline at 12 months endpoint) Status • FPI Q2 2009 • Study met its primary endpoint Q1 • Study met its primary endpoint Q1 • Enrolment completed Q3 2010 2011 2011 • Data to be presented at AAO • Data presented at ADA 2011 • Data presented at ADA 2011 meeting October 2011 • Submitted for FDA approval October • Submitted for FDA approval October 2011 2011Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world.ADA – American Diabetes Association, AAO = American Academy of Opthalmology 59
    • XolairEvaluating potential in Chronic Idiopathic Urticaria, an IgErelated disease Chronic Idiopathic Urticaria Patient Patients who remain symptomatic population despite treatment* Phase III Phase III Phase III Phase/study ASTERIA I ASTERIA II GLACIAL # of patients N=300 N=300 N=320 Design Add-on therapy to H1 anti- Add-on therapy to H1 anti- Add-on therapy to H1 anti- histamines histamines histamines, H2 blockers, and/or 24 week treatment period (q4- 12 week treatment period (q4- LTRA week) week) 24 week treatment period (q4- • ARM A: Xolair 300 mg •ARM A: Xolair 300 mg week) • ARM B: Xolair 150 mg •ARM B: Xolair 150 mg •ARM A: Xolair 300 mg • ARM C: Xolair 75 mg •ARM C: Xolair 75 mg •ARM B: Placebo • ARM D: Placebo •ARM D: Placebo Primary • Change from baseline in UAS7 • Change from baseline in UAS7 • Safety endpoint weekly itch score at Week 12 weekly itch score at Week 12 Status • FPI Q1 2011 • FPI Q1 2011 • FPI Q1 2011 In collaboration with Novartis *Refractory to H1 anti-histamines, H2 blockers, and/or leukotriene receptor antagonists (LTRAs) at the time of randomisation. 60
    • Zelboraf (vemurafenib, RG7204/PLX4032)A selective novel small molecule that inhibitsmutant BRAF• Phase II/III clinical trials Previously untreated Previously treated Previously treated papillary Melanoma patients with Patient metastatic melanoma metastatic melanoma thyroid cancer brain metastases population BRAF mutation positive BRAF mutation positive BRAF mutation positive BRAF mutation positive Phase III Phase II Phase/study BRIM3 BRIM2 Phase II Phase II Global study US and Australia # of patients N=675 N=132 N=40 N=132 Design • ARM A: Zelboraf • Single ARM: Zelboraf • Single ARM: Zelboraf • Single ARM: Zelboraf • ARM B: dacarbazine Primary • Overall survival and progression- • Best overall response rate • Best overall response rate • Overall Response Rate in the endpoint free survival assessed by IRC using brain RECIST criteria Status • Study met both co-primary • Positive data presented at • FPI Q2 2011 • FPI Q3 2011 endpoints Q1 2011 the International Melanoma • Data presented at ASCO 2011 Congress 2010 • FDA granted approval Q3 2011 • Updated data presented at • Updated OS data presented at ASCO 2011 ESMO 2011 Zelboraf in collaboration with Plexxikon Inc., now part of Daiichi Sankyo Group IRC = Independent Review Committee; RECIST = Response Evaluation Criteria in Solid Tumors. 61
    • Zelboraf (vemurafenib, RG7204/PLX4032)A selective novel small molecule that inhibitsmutant BRAF• Phase I clinical trials Previously untreated Melanoma patients with brain Patient metastatic melanoma metastases population BRAF mutation positive BRAF mutation positive Phase/study Phase Ib Phase I # of patients N=20 N=20 Design • Single ARM: Zelboraf plus • Single ARM: Zelboraf ipilimumab Primary • Safety • Safety endpoint Status • FPI Q4 2011 • FPI Q4 2010 Zelboraf in collaboration with Plexxikon Inc., now part of Daiichi Sankyo Group Combination study with ipilimumab is in collaboration with Bristol-Myers Squibb. 62
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group Q3 2011 salesDiagnosticsForeign exchange rate information 63
    • Pertuzumab (RG1273)First in a new class of HER dimerization inhibitors Second-line HER2- First-line HER2- Patient Adjuvant HER2+ breast Neoadjuvant HER2- Neoadjuvant HER2- positive metastatic positive metastatic population cancer positive breast cancer positive breast cancer breast cancer breast cancer Phase III Phase II Phase II Phase II Phase III Phase/study APHINITY TRYPHAENA NeoSphere PHEREXA CLEOPATRA # of patients N=3,806 N=225 N=417 N=450 N=808 Design • ARM A: Herceptin • ARM A: FEC followed • ARM A: Herceptin • ARM A: Xeloda plus • ARM A: Pertuzumab plus chemotherapy by Taxane with plus docetaxel Herceptin plus Herceptin and • ARM B: Herceptin, Herceptin and • ARM B: Herceptin, • ARM B: Xeloda plus docetaxel chemotherapy plus pertuzumab (H+P docetaxel plus Herceptin plus • ARM B: Placebo plus pertuzumab given concurrently) pertuzumab Pertuzumab Herceptin and • ARM B: FEC followed • ARM C: Herceptin docetaxel by Taxane with plus pertuzumab Herceptin + • ARM D: Pertuzumab pertuzumab (H+P plus docetaxel given sequentially) • ARM C: TCH + pertuzumab (H+P given concurrently) Primary endpoint • 3-year disease-free • Safety • Pathologic complete • Progression-free • Progression-free survival response rate survival survival Status • Expect FPI Q4 2011 • FPI Q4 2009 • FPI Q1 2008 • FPI Q1 2010 • Met primary endpoint • Top-line data available • Data presented at July 2011 Q3 2011 SABCS 2010 • Data to be presented • Data to be presented • Biomarker data to be at SABCS 2011 at SABCS 2011 presented at SABCS 2011PET = Positron Emission Tomography; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin;SABCS = San Antonio Breast Cancer Symposium. 64
    • Trastuzumab emtansine (T-DM1) (RG3502)Evaluating new treatment options in HER2+ breast cancer Patients who have Pretreated Patient Neoadjuvant/ Previously untreated progressed on HER2 HER2 pos. metastatic population Adjuvant HER2 pos. metastatic breast cancer targeted treatment breast cancer1 Phase/ Phase III Phase III Randomised Phase III Phase II study TH3RESA EMILIA Phase II MARIANNE # of N=135 N=795 N=980 N=137 N=1,092 patients Design • Single ARM: T-DM1 • ARM A: T-DM1 • ARM A: T-DM1 • ARM A: T-DM1 • ARM A: Herceptin administered • ARM B: physician‟s • ARM B: Xeloda plus • ARM B: Herceptin plus taxane immediately following choice lapatinib plus docetaxel • ARM B: T-DM1 plus completion of pertuzumab anthracycline • ARM C: T-DM1 plus chemotherapy placebo Primary • Cardiac event rate ORR and Overall survival Co-primary endpoints: • Progression-free • Progression-free endpoint • Safety • Progression-free survival by investigator survival assessed by survival (PFS) IRF • Overall survival Status • FPI Q4 2010 • FPI Q3 2011 • FPI Q1 2009 • Enrolment completed • FPI Q3 2010 • Completed enrollment • Enrollment completed Q4 2009 Q2 2011 • Expect PFS data 2012 • Preliminary data • Expect data Q1 2012 • Expect to submit PFS presented at ESMO data for approval in 2010 2012 • Positive topline PFS data April 2011 • Data presented at ESMO 2011In collaboration with ImmunoGenESMO = European Society for Medical Oncology. 651 Patients must have received prior treatment which included both: a taxane, alone or in combination with another agent, and trastuzumab in the adjuvant, locallyadvanced, or metastatic setting.
    • Vismodegib (RG3616/GDC-0449 )A novel small molecule inhibitor of the hedgehog signalingpathway Patient Advanced basal Operable basal population cell carcinoma cell carcinoma Pivotal Phase II Phase/study Phase II ERIVANCE # of patients N=104 N=49 Design • Single ARM: GDC-0449 • Single ARM: GDC-0449 Primary • Overall response rate • COHORT 1: Complete clearance endpoint • COHORT 2: Durable complete clearance Status • Enrolment completed Q1 2010 • FPI Q4 2010 • Positive pivotal phase II results announced March 2011 • Data presented at EADO June 2011, ECCO/ESMO Sep 2011, EADV Oct 2011 • Submitted for FDA approval Q3 2011In collaboration with Curis 66
    • GA101 (RG7159)Type II, glycoengineered anti-CD20 monoclonal antibody• Phase I/II clinical trials Front-line or relapsed Relapsed or refractoryPatient Relapsed indolent non-Hodgkin’s lymphoma non-Hodgkin’s lymphoma or chronicpopulation indolent non-Hodgkin’s lymphoma (NHL) lymphocytic leukaemia (CLL) Phase Ib Phase I/II Phase I/IIPhase/study GAUDI GAUSS GAUGUIN# of patients N=136 N=202 N=133Design • Cohort A: GA101 plus fludarabine + Phase I portion Phase I portion: cyclophosphamide (extended treatment for 2 years): • Single agent: GA101 • Cohort B: GA101 plus CHOP • Single agent: GA101 • Cohort C: GA101 plus bendamustine Phase II portion: Phase II portion • Single agent: GA101 (extended treatment for 2 years): • ARM A: MabThera/Rituxan • ARM B: GA101Status • FPI Q1 2009 Phase I portion: • Phase I portion: • Expect data end of 2011 • Initiated Q1 2008 • Initiated Q3 2007 • Data presented at ASH 2009 • Updated Phase I NHL and CLL data presented at ASH 2009 Phase II portion: • FPI Q3 2009 • Phase II portion: • Enrolment completed Q3 2010 • All cohorts completed enrolment by Q4 • Data to be presented at ASH 2011 2009 • Data presented at ICML/EHA 2011 In collaboration with Biogen Idec 67 CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; ASH = American Society of Hematology; EHA = European Hematology Association.
    • GA101 (RG7159)Type II, glycoengineered anti-CD20 monoclonal antibody• Phase III clinical trials Front-line Indolent chronic lymphocytic non-Hodgkin’s Front-line indolent Patient Diffuse large B-cell leukaemia lymphoma non-Hodgkin’s population lymphoma (DLBCL) Patients with MabThera/Rituxan lymphoma comorbidities refractory Phase/stu Phase III Phase III Phase III Phase III dy CLL11 GADOLIN GALLIUM GOYA # of N=780 N=360 N=1,400 N=1,400 patients Design • ARM A: GA101 plus • ARM A: GA101 plus • ARM A: GA101 plus • ARM A: GA101 plus chlorambucil Bendamustine chemotherapy followed CHOP • ARM B: • ARM B: Bendamustine by GA101 maintenance • ARM B: MabThera/Rituxan plus • ARM B: MabThera/Rituxan plus chlorambucil MabThera/Rituxan plus CHOP • ARM C: Chlorambucil chemotherpy followed by alone MabThera/Rituxan maintenance Primary • Progression-free survival • Progression-free survival • Progression-free survival • Progression-free survival endpoint Status • FPI Q4 2009 • FPI Q2 2010 • FPI Q3 2011 • FPI Q3 2011 • Expect data 2013 • Expect data 2015 In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone 68
    • MetMAb (RG3638)Anti-Met monovalent antibody that inhibitsHGF-mediated activation 1st and 2nd-linePatient 2nd- and 3rd-line metastatic triple negative metastatic breast 1st-line metastatic colorectal cancerpopulation Met diagnostic-positive NSCLC cancerPhase Phase III Phase II Phase II# of patients TBD N=180 N=188Design • ARM A: Tarceva plus MetMAb • ARM A: Avastin and paclitaxel plus • ARM A: FOLFOX plus MetMAb • ARM B: Tarceva plus placebo MetMAb • ARM B: FOLFOX plus placebo • ARM B: Avastin and paclitaxel plus placebo • ARM C: Paclitaxel plus MetMAbPrimary • Overall survival • Progression–free survival • Progression–free survival in ITTendpoint • Progression-free survival in pre- specified Met Dx+ patientsStatus • Expect FPI Q4 2011 • FPI Q1 2011 • FPI Q3 2011 69
    • MetMAb (RG3638)Anti-Met monovalent antibody that inhibitsHGF-mediated activation – Completed StudiesPatient 2nd- and 3rd-line metastatic Solid Tumorspopulation non-small cell lung cancerPhase Phase I Phase II# of patients N=43 N=137Design • Stage 1: MetMAb monotherapy (n=21) • ARM A: Tarceva plus MetMAb (n=69) • Stage 2: MetMAb monotherapy (n=13) • ARM B: Tarceva plus placebo (n=68) • Stage 3: Bevacizumab plus MetMAb (n = 9)Primary endpoint • Safety • Progression–free survival in ITT • Progression-free survival in pre-specified Met Dx+Status • One gastric cancer patient with a complete • Positive data presented at ESMO 2010 response to MetMAb monotherapy • LIP “go” decision Q3 2010 • Final data presented at AACR 2011 • Updated OS data presented at ASCO 2011AACR = American Association ESMO = European Society for Medical Oncology;LIP = Lifecycle Investment Point. ASCO = American Society of Clinical Oncology 70
    • Dalcetrapib (RG1658)A first-in-class CETP modulator• Phase II clinical trials dal-HEART Programme Global Research Initiative Patients with CHD or Patients with CHD and Patient population CHD risk equivalents other CHD risk factors (Safety Study) (Safety Study) Phase IIb Phase IIb Phase/study dal-VESSEL dal-PLAQUE Endothelial function study Imaging study # of patients N=476 N=130 Design • In addition to standard medication • In addition to standard medication (including statins): (including statins): • 36 weeks treatment duration • 24 months treatment duration • ARM A: Dalcetrapib • ARM A: Dalcetrapib • ARM B: Placebo • ARM B: Placebo Primary endpoint • Change from baseline in mean blood • Change from baseline of MRI plaque pressure (4 weeks) size/burden (12 months) • Change from baseline in % flow • Change from baseline in plaque to mediated dilatation (12 weeks) background (blood) ratio from an index vessel by PET/CT (6 months) Status • Initiated Q2 2008 • Initiated Q1 2008 • Enrolment completed Q3 2009 • Enrolment completed Q4 2008 • Data presented at ESC 2011 • Data presented at ESC 2011 In collaboration with Japan Tobacco CHD = Stable coronary heart disease; PET/CT = Positron Emission Tomography/Computed Tomography; MRI = Magnetic Resonance Imaging; 71
    • Dalcetrapib (RG1658) A first-in-class CETP modulator (continued)• Phase III clinical trials dal-HEART Programme Global Research Initiative Patients with CHD, CHD risk Patient Stable CHD patients Patients with evidence of CAD Patients with recent ACS equivalents or at elevated risk population with recent ACS for CVD Phase III Phase III Phase III Phase III Phase/study dal-OUTCOMES dal-PLAQUE 2* dal-ACUTE dal-OUTCOMES 2 Mortality and morbidity study Imaging study Biomarker study Mortality and morbidity study # of patients N=15,872 N=900 N=300 N=20,000 Design • In addition to standard medication • In addition to standard • In addition to standard • In addition to standard for ACS (including statins): medication (including statins): medication (including statins): medication (including statins): • Minimum of 24 months treatment • 24 months treatment duration • 20 weeks treatment duration • Event driven trial - 4 to 5 years duration • Uses both IMT and IVUS • ARM A: Dalcetrapib follow up • ARM A: Dalcetrapib ultrasound imaging techniques • ARM B: Placebo • ARM A: Dalcetrapib • ARM B: Placebo • ARM A: Dalcetrapib • ARM B: Placebo • ARM B: Placebo Primary • Time to first occurrence of any • Assess the change from • To evaluate the effect of • To evaluate the potential of endpoint component of the composite baseline in the progression of dalcetrapib on HDL-C at week dalcetrapib to reduce cardiovascular event atherosclerosis using IMT and 4 when treatment is initiated cardiovascular morbidity and IVUS in coronary and carotid within 1 week of an ACS mortality vascular beds in the same • To evaluate the long-term patients safety and tolerability of dalcetrapib Status • Initiated Q2 2008 • Initiated Q4 2009 • FPI Q1 2011 • in preparation • Enrolment completed Q2 2010 • Recruitment completed • Recruitment completed Q3 • Interim analysis at 50% of events • Expect data end of 2013 2011 occurred in July 2011; DSMB recommended to continue study as planned with no changes In collaboration with Japan Tobacco *Study being conducted in collaboration with the Canadian Atherosclerosis Imaging Network and Montreal Heart Institute 72 CHD = Stable coronary heart disease; ACS = Acute Coronary Syndrome; CAD = Coronary artery disease; CVD = cardiovascular disease; IMT = Intima-Media Thickness; IVUS = Intravascular Ultrasound.
    • Aleglitazar (RG1439)A balanced PPAR co-agonist - potential to reducecardiovascular events in type 2 diabetes patients Type 2 diabetes Patient ACS patients with Patients with moderate and mild population Type 2 diabetes renal impairment Phase II Phase III Phase/study AleNEPHRO AleCARDIO Renal function study Cardiovascular outcomes study # of patients N=300 N=6,000 Design • 52 week treatment duration: • At least 2.5 years treatment period and until • ARM A: Aleglitazar (150 µg) 950 events have occurred • ARM B: Pioglitazone (45 mg) • ARM A: Aleglitazar (150 µg) on top of SOC • ARM B: Placebo on top of SOC Primary • Relative change from baseline in glomerular • Reduction in cardiovascular mortality, non- endpoint filtration rate at 60 weeks fatal myocardial infarction and stroke (MACE) Status • FPI Q2 2010 • FPI Q1 2010 • Enrollment completed Q2 2011 • Expect data end of 2012ACS = Acute Coronary Syndrome; SOC = standard of care. 73
    • Glycine reuptake inhibitor (GlyT-1, RG1678)• Positive phase II (POC study) data presented at the American College of Neuropsychopharmacology, December 2010 Acute Patient Persistent, predominant exacerbation of Sub-optimally controlled symptoms of schizophrenia population negative symptoms of schizophrenia schizophrenia Phase II Phase III Phase III Phase III Phase III Phase III Phase III Phase/study Proof of concept NIGHTLYTE MOONLYTE TWILYTE SUNLYTE DAYLYTE FLASHLYTE study # of N=300 N=600 N=600 N=600 N=630 N=630 N=630 patients Design • 4-week • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy treatment period to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics • ARM A: • 52-week • 52-week • 52-week • 52-week • 52-week • 52-week RG1678 daily treatment period treatment period treatment period treatment period treatment period treatment period (10 mg) • ARM A: • ARM A: • ARM A: • ARM A: • ARM A: • ARM A: • ARM B: RG1678 daily RG1678 daily RG1678 daily RG1678 (10 RG1678 (5 mg) RG1678 (10 RG1678 daily (10 mg) (10 mg) (5 mg) mg) • ARM B: mg) (30 mg) • ARM B: • ARM B: • ARM B: • ARM B: RG1678 (10 • ARM B: • ARM C: RG1678 daily RG1678 daily RG1678 daily RG1678 (20 mg) RG1678 (20 Olanzapine (20 mg) (20 mg) (10 mg) mg) • ARM C: mg) • ARM D: • ARM C: • ARM C: • ARM C: • ARM C: Placebo • ARM C: Placebo Placebo Placebo Placebo Placebo Placebo Primary • PANSS total • PANSS positive • PANSS positive • PANSS positive • PANSS negative • PANSS negative • PANSS negative endpoint symptom factor symptom factor symptom factor symptom factor symptom factor symptom factor symptom factor at week 4 at week 12 at week 12 at week 12 at week 24 at week 24 at week 24 Status • FPI Q1 2011 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 PANSS = Positive and Negative Syndrome Scale 74
    • Ocrelizumab (RG1594)2nd generation anti-CD20 monoclonal antibody Patient Primary progressive populatio Relapsing multiple sclerosis (RMS) multiple sclerosis (PPMS) n Phase/st Phase III Phase III Phase III udy OPERA I OPERA II ORATORIO # of N=800 N=800 N=630 patients Design • 96-week treatment period: • 96-week treatment period: • 120-week treatment period: • ARM A: Ocrelizumab 2x • ARM A: Ocrelizumab 2x • ARM A: Ocrelizumab 2x 300 mg IV followed by 600 300 mg IV followed by 600 300 mg IV every 24 weeks mg IV every 24 weeks mg IV every 24 weeks • ARM B: Placebo • ARM B: Rebif® (interferon • ARM B: Rebif® (interferon -1a) -1a) Primary • Annualized relapse rate at 96 • Annualized relapse rate at 96 • Sustained disability endpoint weeks versus Rebif weeks versus Rebif progression versus placebo by Expanded Disability Status Scale (EDSS) Status • FPI Q3 2011 • FPI Q3 2011 • FPI Q1 2011Rebif is a registered trademarks of EMD Serono, Inc. 75
    • Lebrikizumab (RG3637) development programmeA humanized monoclonal antibody designed to bindspecifically to IL-13 Severe uncontrolled adult asthma Adult patients who are inadequately Adult patients who Patient controlled on inhaled are not taking population corticosteroids inhaled corticosteroids Phase II Phase II Phase/study MILLY MOLLY Proof of concept study Dose-ranging study # of patients N=218 N=212 Design • ARM A: Lebrikizumab • ARM A: Lebrikizumab (low dose) • ARM B: Placebo • ARM B: Lebrikizumab (medium dose) • ARM C: Lebrikizumab (high dose) • ARM D: Placebo Status • Topline data Q3 2010 • FPI Q4 2009 • LIP „go‟ decision Q4 2010 • Topline data: Q1 2011 • Data published in NEJM Aug. 2011 • Phase III „go‟ decision June 2011 • Data presented at ERS 2011LIP = Lifecycle Investment Point 76
    • Mericitabine (RG7128)Nucleoside polymerase inhibitor Treatment-naive and failure Treatment-naive and failurePatient Chronic hepatitis C chronic hepatitis C chronic hepatitis Cpopulation Genotype 2 and 3 Genotype 1 and 4 Genotype 1 and 4 Phase IIb Phase IIbPhase/study JUMP-C Phase IIb PROPEL Longer duration study# of patients N=408 N= 168 TBDDesign • ARM A: RG7128 (500 mg BID) + Pegasys and Copegus for 12 • ARM A: RG7128 (1000 mg BID) + • RG7128 in combination with weeks, followed by Pegasys and Copegus for 12 weeks* Pegasys and Copegus for 24 weeks* Pegasys and Copegus • ARM B: RG7128 (1000 mg BID) + Pegasys and Copegus for 8 *Patients achieving RVR at week 4, weeks, followed by Pegasys and Copegus for 16 weeks* sustained through week 22, will stop all • ARM C: RG7128 (1000 mg BID) + Pegasys and Copegus for 12 treatment at week 24; non-RVR patients weeks, followed by Pegasys and Copegus for 12 weeks* will continue treatment with Pegasys and *Patients who have not achieved rapid viral (RVR) response will Copegus for another 24 weeks up to week receive Pegasys and Copegus for a further 24 weeks. 48. • ARM D: RG7128 (1000 mg BID) + Pegasys and Copegus for 12 • ARM B: Pegasys and Copegus for 48 weeks, followed by Pegasys and Copegus for 36 weeks weeks • ARM E: Pegasys and Copegus for 48 weeks • ARM C (non-responders to ARM B): • ARM F (non-responder to ARM E): RG7128 (1000 mg BID) RG7128 (1000 mg BID) + Pegasys and + Pegasys and Copegus for 24 weeks, followed by Pegasys and Copegus for 24 weeks, followed by Copegus for 24 weeks Pegasys and Copegus for 24 weeksPrimary • Sustained virological response (SVR) • Sustained virological response (SVR)endpointStatus • Cohort 1 - FPI Q2 2009; Cohort 2 – FPI Q4 2009 • FPI Q1 2010 • In preparation • ARM A to E enrolment completed Q1 2010 • ARM A and B enrolment completed Q2 • FPI for ARM F Q3 2010 2010 • Interim data presented at AASLD 2010 • FPI ARM C Q3 2010 • Expect final data presentation at EASL 2012 • Interim data presented at EASL 2011 • Expect final data presentation at EASL 2012Licensed from PharmassetAASLD = American Association for the Study of Liver Disease; EASL = European Association for the Study of the Liver 77
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group Q3 2011 salesDiagnosticsForeign exchange rate information 78
    • Oncology development programmesSmall Molecules Apoptosis MAPK signaling MDM2 antagonist BRAF inhibitor(2) MEK inhibitor Raf/MEK inhibitorMolecule (RG7112) (RG7256) (CIF, RG7167) (CKI27, RG7304) HematologicPatient Advanced solid BRAF mutated neoplasms Solid tumors Solid tumorspopulation tumors solid tumors (Leukaemia)Phase Phase I Phase I Phase I Phase I Phase I# of patients N=105 N=90 N=100 N=115 N=52Design • Multiple ascending • Multiple ascending • Multiple ascending • Dose-escalation, • Dose-escalation to dose-escalation dose-escalation dose study with followed by MTD study study extension cohorts expansion into 4 cohorts in specific indications • Study completed Q2 • Initiated Q2 2008 • FPI Q3 2010 • Initiated April 2008 • Initiated October 2011 • Preliminary results • Go decision Q4 2010 2008 • Data available end of presented at ASH • Phase I study • Phase I studyStatus 2011 2010 and 2011 continuing, further stopped enrolment in • Expect to initiate • Expect to initiate 80 patients being Q4 2010 Phase Ib studies in Phase Ib studies in enrolled 2012 2012Collaborator Plexxikon Chugai Chugai 79Plexxikon Inc., now part of Daiichi Sankyo Group
    • Oncology development programmesMonoclonal Antibodies Angiogenic signaling Anti-PlGF MAb Molecule (RG7334) Patient Glioblastoma multiforme Hepatocellular carcinoma (HCC) population Phase Phase Ib/II Phase Ib # of patients N=80-100 N=60-70 Design Part 1 - Dose escalation portion Part 1 - Dose escalation portion • RG7334 in combination with Avastin • RG7334 in combination with sorafenib Part 2 Part 2 • ARM A: Avastin • ARM A: Sorafenib • ARM B: Avastin plus RG7334 • ARM B: Sorafenib plus RG7334 Primary endpoint • Part 1 - Establish dosing for Part 2 • Part 1 - Establish dosing for Part 2 • Part 2 - PFS at 6 months • Part 2 - Safety, PK, PD Status • FPI Q2 2011 • FPI Q1 2011 Collaborator ThromboGenics & BioInvent 80
    • Oncology development programmesMonoclonal Antibodies (continued) Immunomodulation / Tumor – Apoptosis Induction / Targeted Therapy Stroma Interactions Immune modulation Anti-glypican-3 MAb Anti-CD44 MAb Anti-TWEAK MAb Molecule (GC33, RG7686) (RG7356) (RG7212) Patient Metastatic liver cancer Solid tumors Solid tumors population (hepatocellular carcinoma) Phase Phase Ib Phase I Phase I # of patients N= 40-50 N=50-70 N=100 Design • Study US Monotherapy • Multiple ascending dose study • Multiple ascending dose study • Study Japan Monotherapy with extension and imaging arm with extension cohorts • Combo with SoC dose escalation study Primary • Safety and tolerability • Safety (MTD), PK, PD, preliminary • Safety, PK, PD endpoint activity Status • FPI Q4 2008 • FPI Q2 2011 • FPI Q3 2011 Collaborator ChugaiSoC – standard of care 81
    • GA201 (RG7160)Glycoengineered enhanced ADCC/anti-EGFRmonoclonal antibodyPatient Head and neck squamous cell 1st-line metastatic 2nd-line metastaticpopulation carcinoma non-small cell lung cancer colorectal cancer Phase IPhase Phase Ib/II Phase II Mechanism of action study# of patients N=45 N=160 N=160Design • ARM A: GA201 Treated until disease progression: Treated until disease progression: • ARM B: Cetuximab Squamous KRAS Wild Type ARM A: GA201 plus cisplatin and ARM A: GA201 plus FOLFIRI gemcitabine ARM B: Cetuximab plus FOLFIRI ARM B: Cisplatin and gemcitabine KRAS Mutant Non-Squamous ARM A: GA201 plus FOLFIRI ARM A: GA201 plus cisplatin and pemetrexed ARM B: FOLFIRI alone ARM B: Cisplatin and pemetrexedPrimary • Pharmacodynamic • Part 1 – Safety • PFSendpoint • Part 2 – PFSStatus • FPI Q4 2009 • Part 1 FPI Q4 2010 • FPI Q2 2011 • Recruitment ongoing • Part 2 FPI Q2 2011 82
    • Inflammation development programmes CRTH2 antagonist huMAb IL-17 Molecule (RG7185) (RG4934) Patient Asthma Psoriatic arthritis population Phase Phase I Phase I # of patients N=80 N= 19 Design • Single and multiple doses • Multiple doses Status • Enrolment initiated in healthy volunteers • FPI Q1 2011 in Q3 2010 • Recruitment completed Q3 2011 • Top-line results available Q1 2012 Collaborator 83
    • Virology development programmes Nucleoside polymerase inh (9) DAA Combo Program Molecule (RG7432) (RG7320) Patient Treatment-naïve and Interferon Unable/Intolerant Patients Chronic hepatitis C population Chronic hepatitis C Genotype 1 Phase IIb Phase Phase I INFORM-SVR Interferon-free combination trial # of patients N=60 N=200 Design • Dose-escalation study • ARM A: Ritonavir (100 mg bid) plus danoprevir (100 mg bid) plus RG7128 (1000 mg bid) with Copegus • ARM B: Ritonavir (100 mg bid) plus danoprevir (100 mg bid) plus RG7128 (1000 mg bid) • If patients are virus negative at weeks 2 and 10, patients will be re- randomized to stop therapy at week 12 or receive another 12 weeks of treatment for a total of 24 weeks. • ARM C: Ritonavir (100 mg bid) plus danoprevir (100 mg bid) plus RG7128 (1000 mg bid) with Copegus Primary endpoint • Sustained virological response 24 weeks after the end of study treatment Status • FPI Q4 2010 • FPI Q1 2011 Collaborator Pharmasset 84
    • Danoprevir (RG7227)HCV protease inhibitorPatient Treatment-naïve Treatment-experiencedpopulation chronic hepatitis C patients chronic hepatitis C patients Phase IIb Phase IIb Phase IIb ATLAS DAUPHINE MatterhornPhase/study Danoprevir + Pegasys + Ribavirin in Boosted Danoprevir + Pegasys + Ribavirin in Boosted Danoprevir in Triple, Quad and Interferon-free Genotype 1 Genotype 1 +4 combinations# of patients N=232 N=421 N=381Design • ARM A: Danoprevir 300 mg q8h + Danoprevir boosted by low dose ritonavir Danoprevir boosted by low dose ritonavir in IFN-free, triple Pegasys and Copegus for 12 weeks •ARM A: Ritonavir + Pegasys + Copegus + and QUAD • ARM B: Danoprevir 600 mg q12h + Danoprevir 200 mg for 24 weeks Cohort A: partial responders: Pegasys and Copegus for 12 weeks •ARM B: Ritonavir + Pegasys + Copegus + •ARM A1: Ritonavir + RG7128 1000 mg + Copegus + • ARM C: Danoprevir 900 mg q12h + Danoprevir 100 mg for 24 weeks Danoprevir 100 mg for 24 weeks Pegasys and Copegus for 12 weeks (arm •ARM C: Ritonavir + Pegasys + Copegus + •ARM A2: Ritonavir + Pegasys + Copegus + Danoprevir 100 discontinued) Danoprevir 50 mg for 24 weeks mg for 24 weeks • ARM D: Placebo + Pegasys and Copegus •ARM D: Ritonavir + Pegasys + Copegus + •ARM A3: Ritonavir + RG7128 1000 mg + Pegasys + for 48 weeks Danoprevir 100 mg* Copegus + Danoprevir 100 mg for 24 weeks •ARM E: Pegasys and Copegus Cohort B: null responders: *If patients are virus negative at week 2 and •ARM B1: Ritonavir + RG7128 1000 mg + Copegus + 10, patients will stop therapy at week 12. Danoprevir 100 mg for 24 weeks •ARM B2: Ritonavir + RG7128 1000 mg + Pegasys + Copegus + Danoprevir 100 mg for 24 weeks •ARM B3: Ritonavir + RG7128 1000 mg + Pegasys + Copegus + Danoprevir 100 mg for 24 weeks followed by 24 weeks Pegasys + CopegusPrimary • Sustained virological response 24 weeks • Sustained virological response 24 weeks • Sustained virological response 24 weeks after the end ofendpoint after the end of study treatment after the end of study treatment study treatmentStatus • FPI Q3 2009 • FPI Q4 2010 • FPI Q2 2011 • 900 mg cohort be discontinued in Q4 2009 • Recruitment completed Q1 2011 • Recruitment completed Q3 2011 • SVR results will be presented at AASLD Q4 2011*patients previously treated with Pegasys/RBV with less than a 2-log drop on treatments 85
    • Metabolic development programmes• Phase II studies P-selectin huMAb 11 Beta HSD inhibitor Molecule (RG1512) (RG4929) Acute Coronary Syndrome Prevention of saphenous vein (ACS) Patient graft disease Patients undergoing Metabolic diseases population Patients undergoing coronary artery Percutaneous Coronary bypass graft (CABG) surgery Intervention (PCI) Phase II Phase/study Phase II Phase II Proof of mechanism study # of patients N=384 N=516 N=80 Design 32-week treatment period Single infusion 12-week treatment •ARM A: RG1512 (20 mg/kg) •ARM A: RG1512 (5 mg/kg) •ARM A: RG4929 (200 mg) •ARM B: Placebo •ARM B: RG1512 (20 mg/kg) •ARM B: Placebo •ARM C: Placebo Status • FPI Q4 2010 • FPI Q2 2011 • FPI Q1 2011 • Expect data Q2 2012 Collaborator Genmab 86
    • Metabolic development programmes• Phase II studies GLP-1/GIP dual agonist ABCA1 inducer CatS antagonist Molecule (MAR701, RG7685) (RG7273) (RG7236) Patient Cardiovascular Type 2 diabetes Type 2 diabetes Dyslipidemia population Disease Phase II Phase/study Phase I Proof of concept Phase I Phase I study Design • Multiple • In preparation • Multiple • Multiple ascending ascending dose ascending dose dose study (MAD) study study Status • FPI Q2 2011 • Expect FPI Q4 • FPI Q3 2011 • Expect FPI Q3 2012 • Recruitment 2011 completed Q3 2011 Collaborator Marcadia Biotech, Inc. acquisition 87
    • CNS (Neuroscience) development programmes Gantenerumab GABRA5 negative allosteric modulator (NAM) Molecule (Anti-Αβ, RG1450) (RG1662) Patient Prodromal Alzheimer’s Down Syndrome population Disease Phase I Phase Phase II Phase I # of patients N=360 N=90 N=32 Design 104-week subcutaneous treatment period • Single ascending dose • Multiple ascending • ARM A: Gantenerumab (225 mg) study/PET dose study • ARM B: Gantenerumab (105 mg) • ARM C: Placebo Primary endpoint • Change in Clinical Dementia Rating scale • Food effect, Brain • Safety Sum of Boxes (CDR-SOB) at 2 years Receptor Occupancy, Safety Status • FPI Q4 2010 • FPI Q1 2010 • FPI Q4 2010 • Enrolment completed • Enrollment completed Q3 2011 Collaborator MorphoSys 88
    • CNS (Neuroscience) development programmes Monoamine oxidase type B Triple reuptake inhibitor V1 receptor antagonist Molecule (MAO-B) inhibitor (RG7166) (RG7314) (RG1577, EVT-302) Patient Depression Autism Alzheimer’s Disease population Phase Phase I Phase I Phase I # of patients N=76 TBD Design • Extended MAD –BID dosing • SAD/MAD umbrella protocol Double-blind, placebo controlled including food effect randomized study to assess the efficacy of RG1577 in mild to moderate patients with Alzheimer disease Primary • Safety • Safety, Tolerability • Efficacy endpoint Status • FPI Q4 2009 • FPI Q3 2010 • Expect FPI in H2 2012 Collaborator Evotec 89
    • CNS (Neuroscience) development programmes Metabotropic glutamate receptor pathway mGluR2 antagonist mGluR5 antagonist Molecule (RG1578) (RG7090) Patient Treatment-resistant Depression Fragile X Syndrome population depression Phase/study Phase I Phase IIa Phase IIa # of patients N=104 N=48 N=48 Design • Dose-escalation study  ARM A: RG7090 daily  ARM A: RG7090 ascending dosing (multiple dosing) doses (Multiple dosing)  ARM B: Placebo daily  ARM B: Placebo Primary • Safety and tolerability • Safety and tolerability • Safety and tolerability endpoint Status • Study completed • Phase IIa study completed • Study completed • Additional Phase I studies • Phase IIb study to start Q4 • Next study under ongoing 2011 preparation • Phase IIb expected to start Q4 2011 90
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group Q3 2011 salesDiagnosticsForeign exchange rate information 91
    • Oncology development programmes Angiogenic signaling Anti-angiogenic Anti-EGFL7 MAb Molecule (RG7594) (RG7414) First-line metastatic Patient First-line metastatic Advanced solid tumors Advanced solid tumors non-small cell lung population colorectal cancer cancer Phase Phase Ia/Ib Phase Ib Phase II Phase II Prep # of patients N=~54 N=72 N=100 TBD Design • Dose escalation study • ARM A: Anti-EGFL7 • Anti-EGFL7 plus Avastin • TBD • Phase Ib portion in plus Avastin plus carbo/tax vs Avastin combination with • ARM B: Anti-EGFL7 plus carbo/tax Avastin plus Avastin and paclitaxel • RCC expansion: Anti- EGFL7 plus Avastin Status • FPI Q2 2010 • FPI Q1 2010 • FPI Q2 2011 • Expect FPI Q4 2011 • Phase II “go” decision Q1 2011 • Data presented at ASCO 2011 92
    • Oncology development programmes Growth factor signaling Tumor Immunotherapy Anti-HER3 EGFR DAF Anti-FGFR3 MAb NME MAb Molecule MAb (RG7444) (RG7446) (RG7597) Relapsed refractory Patient t(4;14)-positive multiple Metastatic epithelial metastatic bladder Solid tumors population myeloma tumors cancer Phase Phase I Phase I Phase I Phase I # of patients N=25 N=38 N=66 N=91 Design • Dose escalation study • Dose escalation study • Dose escalation study • Dose escalation study Status • FPI Q4 2010 • FPI Q3 2011 • FPI Q4 2010 • FPI Q2 2011 Collaborator 93
    • Oncology development programmes Antibody drug conjugate (ADC) Anti-CD22 ADC NME ADC NME ADC NME ADC NME ADC NME ADC Molecule (RG7593) (RG7450) (RG7596) (RG7458 ) (RG7599) (RG7598) Patient Hematologic Prostate Hematologic NSCLC and Multiple Ovarian Cancer population malignancies Cancer malignancies ovarian cancer Myeloma Phase Phase I Phase I Phase I Phase I Phase I Phase I # of patients N=76 N=49 N=99 N=57 N=70 N=30-45 Design • Dose • Dose • Dose • Dose • Dose • Dose escalation escalation escalation escalation escalation escalation study study study study study study Status • FPI Q4 2010 • FPI Q1 2011 • FPI Q1 2011 • FPI Q2 2011 • FPI Q2 2011 • FPI Q3 2011 Collaborator Seattle Genetics 94
    • Oncology development programmesSmall molecules PI3K signaling PI3 Kinase inhibitorMolecule (GDC-0941, RG7321) Advanced Solid 1L and 2L 1L HER2-negative 2L HER2-positive 2L metastaticPatient Advanced Solid Tumors or Non- advanced non- 2L ER+ metastatic metastatic breast metastatic breast non-small cellpopulation Tumors Hodgkin’s small cell lung breast cancer cancer cancer lung cancer Lymphoma cancer Phase Ia Phase IaPhase Being conducted Being conducted Phase Ib Phase Ib Phase Ib Phase Ib Phase II Prep in the US in the UK# of N=100 N=55 N=45 N=70 N=30 N=30 N=340patientsDesign • Dose-escalating • Dose-escalating • Single ARM: • Patients who have • ARM A: GDC- • Single ARM: • ARM A: GDC- study study Evaluating GDC- progressed on 0941 plus Evaluating GDC- 0941 plus 0941 plus Herceptin-based carboplatin/ 0941 plus Tarceva hormonal therapy paclitaxel and treatment paclitaxel • ARM B: GDC- • Study includes Avastin • ARM A: GDC- (Avastin-ineligible 0980 plus multiple myeloma 0941 plus T-DM1 patients) hormonal therapy extension cohort • ARM B: GDC- • ARM B: GDC- • ARM C: 0941 plus 0941 plus Hormonal therapy Herceptin carboplatin/ paclitaxel plus Avastin (Avastin- eligible patients)Status • FPI Q4 2007 • FPI Q1 2008 • FPI Q3 2009 • FPI Q3 2009 • FPI Q4 2009 • FPI Q3 2009 • Expect FPI Q4 • Additional data • Additional data • Data presented at • Data presented at 2011 presented at presented at SABCS 2010 ASCO 2011 ASCO 2010 and ASCO 2010, ESMO 2010 ESMO 2010, and ASCO 2011 95
    • Oncology development programmesSmall molecules (continued) PI3K signaling PI3 Kinase/mTOR dual inhibitorMolecule (GDC-0980, RG7422) Refractory solid Refractory solidPatient tumors or tumors or Metastatic breast Solid tumors Solid tumors Renal cell carcinomapopulation non-Hodgkin’s non-Hodgkin’s cancer lymphoma lymphomaPhase Phase Ia Phase Ia Phase Ib Phase Ib Phase Ib Prep Phase II Prep# of patients N=75 N=65 N=65 N=80 N=95 N=80Design • Dose escalation study • Dose escalation study • Dose escalation study • Dose escalation study • ARM A: GDC-0980 • ARM A: GDC-0980 • ARM A: GDC- • ARM A: GDC- + Xeloda • ARM B: Everolimus 0980 plus 0980 plus • ARM B: GDC-0980 paclitaxel carboplatin and plus FOLFOX and • ARM B: GDC- paclitaxel Avastin 0980 plus Avastin • ARM B: GDC- and paclitaxel 0980 plus Avastin, • ARM C: GDC- carboplatin and 0980 plus paclitaxel Herceptin and paclitaxelStatus • FPI Q2 2009 • FPI Q2 2009 • FPI Q4 2010 • FPI Q2 2011 • Expect FPI Q4 2011 • Expect FPI Q4 2011 • Data presented at • Data presented at ASCO 2010, ESMO ASCO 2010 and 2010, and ASCO 2011 ESMO 2010ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. 96
    • Oncology development programmesSmall molecules (continued) PI3K signaling Apoptosis Bcl-2 selective PI3 Kinase inhibitor NME IAP Antagonist ChK1 inhibitor Molecule inhibitor (GDC-0032, RG7604) (GDC-0349, RG7603) (GDC-0917, RG7459) (GDC-0425, RG7602) (GDC-0199, RG7601) Relapsed or Patient Solid tumors or Solid tumors or Solid tumors Solid tumors or NHL refractory CLL and population lymphoma lymphoma NHL Phase Phase I Phase Ia Phase I Phase I Phase I # of patients N=45 N=72 N=65 N=36 N=75 Design • Dose escalation • Dose escalation • Dose escalation • Single arm: GDC- • Dose escalation study study study 0199 study Status • FPI Q1 2011 • FPI Q2 2011 • FPI Q4 2010 • FPI Q2 2011 • FPI Q3 2011 Collaborator Abbott and WEHI Array BioPharma WEHI = The Walter and Eliza Hall Institute 97
    • Oncology development programmesSmall molecules (continued) AKT pathway MAPK signaling MEK Inhibitor AKT Inhibitor MEK Inhibitor Molecule (GDC-0623, (GDC-0068, RG7440) (GDC-0973, RG7421) RG7420) Metastatic melanoma Patient Solid tumors Solid tumors Solid tumors Solid tumors Solid tumors BRAF mutation population positive Phase Ib Phase Phase Ia Phase Ib Phase I Phase I Phase Ib BRIM7 # of patients N=57 N=90 N=62 N=90 N=212 N=~50 Design • Dose • Dose escalation • Dose • Dose escalation • Dose escalation • Dose escalation study escalation with either escalation study study evaluating evaluating Zelboraf* study docetaxel or study GDC-0973 plus plus GDC-0973 fluoropyrimidine GDC-0941 (PI3 plus oxaliplatin Kinase Inhibitor) Status • FPI Q1 2010 • FPI Q3 2011 • FPI Q2 2010 • FPI Q2 2007 • FPI Q4 2009 • FPI Q1 2011 • Data • Data presented • Preliminary data presented at AACR 2011 presented at at ASCO • Recruitment AACR and ASCO 2011 completed Q3 2011 2011 Collaborator Array BioPharma Exelixis*Zelboraf in collaboration with Plexxikon Inc., now part of Daiichi Sankyo Group 98
    • Navitoclax (RG7433) development programmeSmall molecule designed to restore apoptosis by blockingthe function of pro-survival Bcl-2 family proteins• Phase I studies Relapsed or refractory Relapsed orPatient Solid tumors CD20+ refractory chronicpopulation lymphoid malignancies lymphocytic leukaemia Phase I/Ib Phase Ib Phase Ib Phase Ib Phase Ib Phase IbPhase M11-958 M10-338 M10-588 M10-589 M10-166 M10-458# of patients N=51 N=50 N=48 N=35 N=29 N=36Design • ARM A: • Single ARM: • Single ARM: • Single ARM: • Single ARM: • ARM A: Navitoclax+ Navitoclax + Navitoclax+ Navitoclax+ Navitoclax + Navitoclax + Rituxan fludarabine, Tarceva docetaxel gemcitabine paclitaxel cyclophosphamide and • ARM B: Rituxan (FCR) Navitoclax+Irin • ARM B: Navitoclax + otecan bendamustine and • ARM C: Rituxan (BR) Navitoclax aloneStatus • FPI Q4 2009 • FPI Q3 2009 • FPI Q3 2009 • FPI Q3 2009 • FPI Q3 2009 • FPI Q4 2009 • Enrollment • Enrollment • Data presented at ASH • Data presented at ASH completed Q3 completed Q3 2010 2010 2011 2011 • Enrollment completed Q4 2010 In collaboration with Abbott 99
    • Navitoclax (RG7433) development programmeSmall molecule designed to restore apoptosis by blockingthe function of pro-survival Bcl-2 family proteins• Phase II studies Relapsed or Patient Relapsed or refractory Front-line chronic refractory chronic population lymphoid malignancies lymphocytic leukaemia lymphocytic leukaemia Phase I/IIa Phase I/IIa Phase II Phase M06-814 M06-873 FRANC # of patients N=84 N=60 N=120 Design • Single ARM: Navitoclax • Single ARM: Navitoclax • ARM A: Rituxan • ARM B: Rituxan + navitoclax for a maximum of 12 weeks • ARM C: Rituxan + navitoclax until progression, relapse, or unacceptable toxicity Status • FPI Q4 2006 • FPI Q3 2007 • FPI Q3 2010 • Initiated Phase IIa cohort Q1 • Initiated Phase IIa cohort Q3 2010 2009 • Updated Phase I data presented • Data presented at ASH 2010 at ASH 2009 • Enrolment completed Q3 2010 • Enrolment completed Q4 2010 In collaboration with Abbott ASH = American Society of Hematology 100
    • Immunology development programmes Anti-LT α Anti-M1 prime rhuMAb-β7 Rontalizumab Molecule (RG7416) (RG7449) (RG7413) (Anti-IFN α, RG7415) Patient Rheumatoid Ulcerative Systemic lupus Asthma population arthritis colitis erythematosus Phase/stud Phase IIa Phase IIa Phase II Phase II Phase I y ALTARA SOLARIO EUCALYPTUS ROSE # of N=200 N=28 N=48 N=120 N=238 patients • ARM A: Anti-LT alpha • ARM A: Anti-M1 • Dose escalation study • ARM A: RhuMAb- • ARM A: Placebo plus DMARD prime β7 (100 mg) plus • Part 1 – IV (leflunomide or • ARM B: Placebo immunosuppressant • Part 2 - Subcutaneous methotrexate) • ARM B: RhuMAb- • ARM B: Rontalizumab • ARM B: Humira® plus β7 (300 mg) plus • Part 1 – IV Design DMARD (leflunomide immunosuppressant • Part 2 – Subcutaneous or methotrexate) • ARM C: Placebo • ARM C: Placebo plus plus DMARD (leflunomide immunosuppressant or methotrexate) • Disease Activity Score • Late airway response • Safety and tolerability • Clinical Remission • Proportion of responders Primary (DAS28) at Day 85 (LAR) at Day 86 (Mayo Clinic Score) at Week 24 endpoint at Week 10 Status • FPI Q4 2010 • FPI Q4 2010 • Enrolment completed • FPI Q3 2011 • FPI Q3 2009 • Enrollment completed Q3 2010 • Enrolment completed Q3 Q2 2011 • Phase II “go” decision 2010 Q1 2011 • Phase IIb go/no go decision Q4 2011DMARD = Disease-Modifying Anti-Rheumatic DrugsHumira® (adalimumab) is a registered trademark of Abbott Laboratories. 101
    • Metabolism, neuroscience and ophthalmologydevelopment programmes Anti-Αβ Anti-Factor D Anti-oxLDL NMEMolecule (RG7412) (RG7417) (RG7418, BI-204) (RG7652) Geographic Atrophy (GA) Secondary prevention ofPatient Alzheimer’s Metabolic secondary to age-related cardiovascular events inpopulation Disease diseases macular degeneration patients with ACS Phase II Phase II Prep Phase Ib/II Phase IIPhase/study ABBY BLAZE Phase II MAHALO Proof of activity study Cognition study Biomarker study# of patients N=360 N=72 N=134 N=120 N=70Design • ARM A: Anti-Abeta • ARM A: Anti-Abeta • Part 1: Open-label • ARM A: Anti-oxLDL (single • Randomized, subcutaneous subcutaneous • Multiple dosing dose) and statin placebo • ARM B: Anti-Abeta • ARM B: Anti-Abeta • Part 2: Randomised • ARM B: Anti-oxLDL controlled single IV IV • ARM A: Anti-Factor D (repeating dose) and statin and multiple • ARM C: Placebo • ARM C: Placebo injection • ARM C: Placebo and statin dose study • ARM B: Sham InjectionPrimary • Change in • Change in brain • Change in TBR as measured • Safety andendpoint cognition (ADAS- amyloid load from • Part 1: Safety by FDG-PET/CT at week 12 tolerability cog) from baseline baseline to week 69 • Part 2: Growth rate of GA to week 73 lesion at month 12Status • FPI Q2 2011 • FPI Q3 2011 • Part 1 FPI Q4 2010 • FPI Q1 2011 • FPI Q3 2011 • Part 2 FPI Q2 2011Collaborator AC Immune BioInventTBR = Target-to-background ratio; FDG = Fluoro-2-deoxy-D-glucose;ACS – acute coronary syndrome. PET = Positron Emission Tomography; CT = CAT scan. 102
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group YTD Sept 2011 resultsDiagnosticsForeign exchange rate information 103
    • Geographical sales split by division and Group* YTD Sept YTD Sept % change CHF m 2010 2011 in CER Pharmaceuticals Division 28,395 24,397 -1 United States 10,878 9,104 +1 Western Europe 7,295 6,210 -4 Japan 3,137 2,712 -6 International 7,085 6,371 +1 Diagnostics Division 7,732 7,095 +6 United States 1,800 1,549 +4 Western Europe 3,081 2,758 +1 Japan 384 375 +6 International 2,467 2,413 +12 Group 36,127 31,492 0 United States 12,678 10,653 +2 Western Europe 10,376 8,968 -2 Japan 3,521 3,087 -4 International 9,552 8,784 +4 104* Geographical sales split shown here does not represent operational organization; CER = Constant Exchange Rates (average full year 2010)
    • CER sales growth (%)Quarterly development 2010 vs. 2009 2011 vs. 2010 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Pharmaceuticals Division 10 -2 -5 -8 -2 -1 0 excl. Tamiflu 8 3 4 4 1 1 0 United States 10 -5 -1 -8 2 1 1 excl. Tamiflu 6 2 4 2 2 2 1 Western Europe 4 -2 -11 -13 -4 -4 -3 excl. Tamiflu 9 2 -1 -2 -4 -4 -4 Japan -9 -3 -22 -11 -7 -3 -7 excl. Tamiflu 2 1 2 7 1 -2 -5 International 25 4 5 -1 -3 0 5 excl. Tamiflu 16 6 12 13 6 6 6 Diagnostics Division 9 9 7 6 6 5 6Roche Group 9 0 -3 -5 0 0 1 excl. Tamiflu 9 4 5 4 2 2 2CER = Constant Exchange Rates (average full year 2010) 105
    • Pharma Division sales YTD Sept 2011 (vs. 2010)Top 20 products Global US W. Europe Japan International % % % % % CHF m CER CHF m CER CHF m CER CHF m CER CHF m CERMabThera/Rituxan 4,417 7 2,024 6 1,182 6 177 0 1,034 10Avastin 3,942 -8 1,774 -15 1,092 -10 438 9 638 9Herceptin 3,905 8 1,056 5 1,463 3 204 2 1,182 19Lucentis 1,128 26 1,128 26 - - - - - -Pegasys 1,051 -5 222 -11 227 -5 69 -15 533 -2Xeloda 1,001 6 377 12 201 -2 80 -6 343 7Tarceva 921 6 347 6 283 -3 64 6 227 20CellCept 770 -12 158 -13 220 -29 45 13 347 0NeoRec./Epogin 690 -22 - - 240 -28 246 -23 204 -13Bonviva/Boniva 551 -19 246 -28 170 -14 - - 135 0Xolair 446 10 446 10 - - - - - -Actemra/RoActemra 433 86 98 267 143 66 132 29 60 217Valcyte/Cymevene 425 9 192 2 120 6 - - 113 28Pulmozyme 358 9 208 12 76 4 - - 74 6Activase/TNKase 331 15 300 16 - - - - 31 7Tamiflu 301 -57 170 2 21 625 69 -60 41 -89Nutropin 242 -6 235 -5 - - - - 7 -7Mircera 237 45 - - 133 14 31 - 73 59Madopar 222 8 - - 70 0 16 3 136 13Neutrogin 200 -13 - - - - 200 -13 - -CER = Constant Exchange Rates (average full year 2010) 106
    • Pharma Division CER sales growth1 in %Global top 20 products Q3/10 Q4/10 Q1/11 Q2/11 Q3/11MabThera/Rituxan 6 10 7 6 7Avastin 7 2 -6 -9 -10Herceptin 8 5 8 12 4Lucentis 34 20 35 29 17Pegasys -8 9 -15 -7 6Xeloda 16 14 7 2 10Tarceva 9 0 8 1 10CellCept -14 5 -14 -13 -9NeoRecormon/Epogin -16 -18 -22 -18 -28Bonviva/Boniva 2 -13 -15 -19 -24Xolair 10 5 13 9 9Actemra/RoActemra 176 158 111 90 69Valcyte/Cymevene 11 14 8 10 8Pulmozyme 2 -5 8 9 11Activase/TNKase 15 -3 23 18 5Tamiflu -90 -94 -47 -88 -51Nutropin 19 11 8 1 -21Mircera 37 37 30 21 82Madopar 11 7 8 7 8Neutrogin -23 -18 -24 -4 -111 Q3-Q4/10 vs. Q3-Q4/09, Q1-Q3/11 vs. Q1-Q3/10 107CER = Constant Exchange Rates (average full year 2010)
    • Pharma Division CER sales growth in %Top 20 products by region US Western Europe Japan International Q41 Q11 Q21Q31 Q41 Q11 Q21 Q31 Q41 Q11 Q21 Q31 Q41 Q11 Q21 Q31MabThera/Rituxan 6 5 7 7 5 5 6 8 16 9 -5 -1 25 15 5 9Avastin -10 -14 -15 -16 -3 -8 -12 -9 50 22 7 2 32 16 8 5Herceptin 7 3 7 4 1 1 5 4 -10 -3 30 -23 13 25 23 9Lucentis 20 35 29 17 - - - - - - - - - - - -Pegasys 6 -28 -17 15 2 -2 -3 -10 5 -2 -12 -28 16 -16 -3 15Xeloda 10 13 2 23 7 -4 -1 -1 33 2 -9 -9 21 10 5 6Tarceva -6 10 1 7 -5 -2 -12 6 45 22 0 2 10 16 22 23CellCept 40 -27 -12 2 -7 -24 -27 -35 25 16 9 15 3 -1 -5 5NeoRecorm/Epogin - - - - -30 -30 -28 -26 -11 -15 -11 -42 -7 -17 -13 -8Bonviva/Boniva -21 -19 -31 -36 -2 -10 -12 -21 - - - - -6 -9 2 7Xolair 5 13 9 9 - - - - - - - - - - - -Actemra/RoActemra - * 356153 114 88 67 51 74 35 27 25 458 338 203 177Valcyte/Cymevene 18 8 3 -4 7 1 11 8 - - - - 13 18 24 42Pulmozyme 2 11 11 14 1 1 6 5 - - - - 22 5 3 12Activase/TNKase -3 24 20 5 - - - - - - - - 5 13 1 7Tamiflu -89 15 -56 - - 169 - * -89 -61 -68 -55 -99 -90 -97 -62Nutropin 11 8 1 -21 - - - - - - - - -5 -15 -7 1Mircera - - - - 20 11 16 15 - - - - 94 86 32 65Madopar - - - - 4 -2 -5 6 5 10 1 -2 9 14 15 10Neutrogin - - - - - - - - -18 -24 -4 -11 - - - -1 Q4/10 vs. Q4/09, Q1-Q3/11 vs. Q1-Q3/10 * > 500% 108CER = Constant Exchange Rates (average full year 2010)
    • Pharma Division sales YTD Sept 2011 (vs. 2010)Recently launched products Global US W. Europe Japan International % % % % % CHF m CER CHF m CER CHF m CER CHF m CER CHF m CERActemra/RoActemra 433 86 98 267 143 66 132 29 60 217Mircera 237 45 - - 133 14 31 - 73 59Zelboraf 11 - 11 - - - - - - -CER = Constant Exchange Rates (average full year 2010) 109
    • Pharma Division Sales GrowthImpact of healthcare reforms and austerity measures 2010 vs. 2009 2011 vs. 2010 Quarterly growth rates % in LC Q1 Q2 H1 Q3 Q4 FY Q1 Q2 H1 Q3 Pharmaceuticals Division 10 -2 4 -5 -8 -2 -2 -1 -1 0 excl. Tamiflu 8 3 6 4 4 5 1 1 1 0 excl. Healthcare Reforms 9 5 7 7 7 7 3 1 2 1 Impact of Healthcare Reforms US healthcare reforms 0.4 1.0 0.7 0.6 0.8 0.7 0.5 -0.3 0.1 0.6 European austerity measures - 0.4 0.3 1.1 1.5 0.2 1.0 0.9 0.9 0.4 Japan pricing regulations - 0.8 0.4 1.0 1.1 0.4 0.9 0.0 0.4 0.0 110
    • YTD Sept 2011: Oncology franchise* Oncology sales US • Sales driven by Rituxan, Herceptin and 18 +1%1 Xeloda; Avastin in mBC bottoming out 15 Western Europe -1% • Continued growth of MabThera and 12 +11% Herceptin, significant impact of austerityCHF bn measures 9 -2% International 6 • Growth driven by major oncology products: 3 Herceptin, MabThera and Avastin -2% Japan 0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 • Avastin is the major growth driver 07 08 09 10 11 Japan International Western Europe US 111 1CER; * YTD Sept 2011 sales: CHF 14.2 bn
    • MabThera/Rituxan Global sales Regional sales Local growth +7%1 US +6% 5.0 4.0CHF bn 3.0 International +10% 2.0 Japan +0% 1.0 Western Europe +6% 0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 07 08 09 10 11 YTD sales of CHF 4.417 bn • 1L maintenance in follicular NHL (Q2 „11): top 5 EU penetration rate doubled to ~ 62% from ~31% in Q4 2010. Adoption of 12-infusion maintenance schedule in top 5 EU ~50% in Q2 „11 from ~39% in Q4 „10. We expect further growth in both measures. • CLL: as of Q2 2011 top 5 EU 1st line CLL penetration rate 65% (vs 62% in Q4 2010; 61% in Q2 2010; 56% in Q4 2009) • RA: Phase IV data at upcoming ACR to demonstrate benefits of switching to MabThera/Rituxan after a single TNF inadequate response. 1121 CER
    • Avastin Global sales Regional sales Local growth - 8%1 US -15% 6.0 5.0 Japan +9%CHF bn 4.0 3.0 2.0 International +9% 1.0 0.0 Western Europe -10% YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 07 08 09 10 11 Avastin New Patient Shares 1st line mCRC 1st line mBC 1st line mNSCLC EU: stable (Q2 „11) EU: stabilizing (Q2 „11) EU: stable (Q2 „11) US: stable (Q3 „11) US: Q3 ‟11 low patient share bottoming US: stable (Q3 „11) Japan: high penetration out Japan: penetration still low Peak sales reconfirmed at CHF 7bn 113 1 CER
    • Herceptin Global sales Regional sales Local growth Western Europe +3% 5.0 +8%1 4.0 US +5%CHF bn 3.0 2.0 1.0 Japan +2% International +19% 0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 07 08 09 10 11YTD sales of CHF 3.905 bn• US2‬ adjuvant use in eBC strong with high stable penetration ~95%; 1st line mBC use steady at about 85%. :• Western Europe‬(top 5 EU, Q2 „11): penetration in eBC stable ~85%, 1st line mBC use stable in the 70% range.• US‬and WE: Stable treatment duration in eBC > 47 weeks.• Metastatic gastric cancer: HER2 testing rate above 80% in EU and US• ‬ merging markets: E Expanded access lead to volume increase of +32.0% in Asia , +22.1% in CEMAI and +31.2% in LatAm. 1141 CER; 2 penetration is reported as Herceptin eligible patients in the US, and as total patient share in top 5 EU
    • Xeloda Global sales Regional sales Local growth International +7% 1.2 +6%1 1.0 Western Europe -2%CHF bn 0.8 0.6 0.4 Japan -6% 0.2 US +12% 0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 07 08 09 10 11YTD sales of CHF 1.001 bn• In US, increased use in adjuvant CC and monotherapy use in 1L metastatic BC• Global sales further benefit from stomach cancer indication in China, expanded metastatic colorectal cancer and inoperable advanced or recurrent stomach cancer in Japan.• WE sales impacted by austerity measures. 1151 CER
    • Tarceva Global sales Regional sales Local growth +6%1 Western Europe -3% 1.2 1.0 Japan +6% 0.8CHF bn 0.6 US +6% 0.4 0.2 International +20% 0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 07 08 09 10 11 YTD sales of CHF 921 m • US: Q3‟11 NSCLC overall penetration remain stable • EU: Market penetration in mNSCLC, top 5 EU (Q1 ‟11): 2nd line: ~40%; Pricing pressure and competitive challenges continue. • International: strong growth 116 1 CER
    • Inflammation/Autoimmune/Transplantation IAT sales YTD Sept 2011 IAT sales: CHF 2.1 bn • Strong growth of Actemra and MabThera/Rituxan compensated for the 2.5 +8%1 further CellCept decline in US and WE 2.0 +18%1 Actemra/RoActemra Sales: CHF 433 m (+86%)CHF bn 1.5 +9%1  Further gain of patient share in all treatment 1.0 lines according to label; US biggest growth -2%1 contributor 0.5 +14%1 CellCept 0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 Sales: CHF 770m (-12%) 07 08 09 10 11 • Patent expiry key EU countries end 2010 • US prescription share ~14% (Q3 „11) Japan International Western Europe US 117 1 CER
    • Tamiflu quarterly sales 2008 - 2011Retail and Governments/CorporationsCHF m1150 Retail Governments & Corporations 950 267 663 750 550 260 95 350 97 727 533 422 233 349 23 150 75 304 233 65 170 7 106 91 48 7 45 50 -1 36 17 19 45 3 -6 -50 Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 118
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group YTD Sept 2011 resultsDiagnosticsForeign exchange rate information 119
    • YTD Sept 2011: Diagnostics sales by regionDriven by Asia-Pacific, EMEA and North America CHF 7,095 m sales growth (CER) Diagnostics Division 6% 1759 North America 25% North America 4% 3546 Latin America 7% EMEA* 2% 489 Latin 15% 926 Asia Pacific 13% America 375 Asia 17% Japan 5% Pacific EMEA1 50% Japan 6%1Europe, Middle East and Africa 120CER = Constant Exchange Rates (average full year 2010)
    • Diagnostics Division quarterly sales and local growth1 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 CHF m % CER CHF m % CER CHF m % CER CHF m % CER CHF m% CER CHF m% CERProfessional 1,279 12 1,153 9 1,256 13 1,165 10 1,182 7 1,083 10DiagnosticsDiabetes 781 5 702 4 768 2 643 1 686 2 609 2CareMolecular 310 4 296 7 289 1 274 3 270 2 257 3DiagnosticsApplied 223 9 197 -2 222 -7 198 -3 179 -5 167 1ScienceTissue 139 14 134 18 148 15 128 18 131 15 123 11DiagnosticsDia Division 2,732 9 2,482 7 2,683 6 2,408 6 2,448 5 2,239 61 versus same period of prior year 121CER = Constant Exchange Rates (average full year 2010)
    • YTD Sept 2011: Diagnostics Division local salesBy Region and Business Area (vs. 2010) Global North America EMEA RoW % CER % CER % CER % CER CHF m growth CHF m growth CHF m growth CHF m growthProfessional Dia 3,430 9 611 9 1,752 4 1,067 18Diabetes Care 1,938 1 420 -6 1,164 2 354 12Molecular Dia 801 3 270 8 322 -4 209 6Applied Science 544 -2 208 2 216 -6 120 -4Tissue Diagnostics 382 15 250 12 92 17 40 30Division 7,095 6 1,759 4 3,546 2 1,790 14CER = Constant Exchange Rates (average full year 2010) 122
    • YTD Sept 2011: Professional DiagnosticsStrong growth driven by immunoassays CHF bn 2011 vs. 2010 CER growth 4.0 +9% 3.0 +7% 2.0 +6% 1.0 +13% 0.0 YTD 9 09 YTD 9 10 YTD 9 11 Other POC products Clinical Chemistry Immunoassay 123CER = Constant Exchange Rates (average full year 2010)
    • YTD Sept 2011: Diabetes CareFDA approval of maltose-independent Aviva PlusBGM system CHF bn 2011 vs. 2010 CER growth 2.5 +1% 2.0 -3% 1.5 1.0 +2% 0.5 0.0 YTD 9 09 YTD 9 10 YTD 9 11 Blood Glucose Insulin Delivery 124CER = Constant Exchange Rates (average full year 2010)
    • YTD Sept 2011: Molecular DiagnosticsHIV and HBV viral load tests drive growth CHF m 2011 vs. 2010 CER growth 1000 +3% 800 600 +2% 400 +2% 200 0 YTD 9 09 YTD 9 10 YTD 9 11 Other Blood Screening Virology 125CER = Constant Exchange Rates (average full year 2010)
    • Applied SciencePressure on research spending globally CHF m 2011 vs. 2010 CER growth 750 -2% 600 450 -12% 300 +12% 150 -4% 0 YTD 9 09 YTD 9 10 YTD 9 11 qPCR&NAP Custom Biotech (industrial) Genomic Analysis (seq+array) Other 126CER = Constant Exchange Rates (average full year 2010)
    • YTD Sept 2011: Tissue DiagnosticsStrong growth in all regions CHF m 2011 vs. 2010 CER growth 400 +15% +19% 300 200 +15% 100 0 YTD 9 09 YTD 9 10 YTD 9 11 Other Primary Staining Advanced Staining 127CER = Constant Exchange Rates (average full year 2010)
    • 2011: Key planned product launchesProfessional Diagnostics Product Description Region Time Vitamin D total Measure vitamin D2 and D3 with greater precision EU H1 √ HE4 Tumor marker used in risk assessment of ovarian EU H1 √ cancer in patients with pelvic mass (with CA125) cobas c 702 Clinical Chemistry module with throughput around EU Q1 √ module for cobas 2,000 tests/hour for high-volume laboratories. 8000 modular Features automated reagent loading, enabling US Q2 √ analyzer series consolidation of a broader test menu. cobas b 123 POC Benchtop multi-parameter analyser for blood gas, US H2 system electrolytes, CO-oximetry and metabolites. For use in critical care settings at the point of carePlanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 128EU = European Union; US = United States
    • 2011: Key planned product launchesDiabetes Care Product Description Region Time Accu-Chek Next-generation strip-free blood glucose monitoring EU H2 Mobile LCM system with an integrated lancing device, significantly smaller than current version and with enhanced functionality Accu-Chek Interactive insulin delivery system combining an insulin US H2 Combo pump (Accu-Chek Spirit Combo) and a blood glucose meter (Accu-Chek Aviva Combo) with broad data management capabilities; the meter also functions as a pump remote control Accu-Chek Nano Sleek version for high-frequency testers offering an US H2 enhanced feature setPlanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 129EU = European Union; US = United States
    • 2011: Key planned product launchesMolecular Diagnostics Product Description Region Time cobas 4800 HPV Test detects HPV 16 and HPV 18 individually and 12 US H2 √ other high-risk genotypes in a pooled result (cervical cancer) cobas 4800 EGFR for identification of mutations in the EGFR gene EU H2 Mutation Test (non-small cell lung cancer) cobas 4800 KRAS for identification of mutations in the KRAS gene EU H2 √ Mutation Test (colon cancer) cobas 4800 BRAF for identification of the V600 mutation in the BRAF EU, US H2 √√ V600 Mutation Test gene (metastatic melanoma)Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 130EU = European Union; US = United States
    • 2011: Key planned product launchesApplied Science Product Description Region Time GS G Type HLA For HLA genotyping on the GS Junior System of GS FLX Global H1 √ primer Sets System GS FLX Titanum- New sequencing chemistry; enables extended read Global H1 √ XL lengths on the GS FLX system Roche Ultra-high resolution arrays for CGH validation and Global H2 Nimblegen 4.2M combined CGH/SNP validation with 4.2 million and 2.1 CGH and 2.1M million features for discovery of variations in gene copy CGH/SNP arrays numbers and single nucleotidesPlanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 131EU = European Union; US = United States
    • 2011: Key planned product launchesTissue Diagnostics Product Description Region Time ER/PR antibody for To support the diagnosis of breast cancer on US H2 IHC testing BenchMark ULTRA HER2 Dual Colour ISH To support the diagnosis of breast cancer US H1 √ Probe for ISH testing OptiView Next-generation detection system for BenchMark US, EU H1 √√ platforms; delivers greater specificity, sensitivity, flexible detection options and improved turn- around timePlanned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 132EU = European Union; US = United States
    • Roche Group development pipelineMarketed products development programmesRoche Pharma global development programmesRoche Pharma research and early developmentGenentech research and early developmentRoche Group YTD Sept 2011 resultsDiagnosticsForeign exchange rate information 133
    • CHF / USD Monthly averages1.151.101.05 20101.000.950.90 20110.850.800.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages1.151.101.05 20101.000.95 -11% -16% -18%0.900.85 20110.80 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 134
    • CHF / USD1.15 monthly avg 20101.10 average YTD 09 20101.05 average full year 20101.000.95 -18%0.90 average YTD 09 20110.850.80 monthly avg 20110.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 135
    • CHF / EUR Monthly averages1.501.451.40 20101.351.301.251.20 20111.151.10 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages1.501.45 20101.401.351.30 2011 -12% -11% -12%1.251.20 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 136
    • CHF / EUR1.501.45 average YTD 09 20101.40 average full year 20101.351.30 monthly avg 2011 monthly avg 2010 -12%1.25 average YTD 09 20111.201.151.10 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 137
    • Average exchange rates YTD 09 11 YTD 09 10 YTD 09 11 vs. YTD 09 10USD 0.88 1.07EUR 1.24 1.40JPY 1.09 1.19 -18% -15% -12% -9% -6% -3% 0% 138
    • Exchange rate impact on sales growthNegative impact from all currencies, inparticular from USD and EURDevelopment ofaverage exchange rates versus prior year periodCHF / EUR -12.1 % -11.5 % -11.8 %CHF / USD -10.9 % -16.3 % -17.5 %CHF / JPY -1.7 % -6.6 % -8.3 % Differencein CHF / CER -9.1 %pt -12.1 %pt -13.2 %pt growth 0.4% -0.1% 0.1% Sales growth CER CHF 2011 growth growth vs. 2010 -9.2% -12.0% -12.8% Q1 HY YTD 9 FYCER = Constant Exchange Rates (average full year 2010) 139
    • Exchange rate impact on sales growthNegative impact from all currencies, inparticular from USD and EURDevelopment ofaverage exchange rates versus prior year periodCHF / EUR -12.1 % -11.1 % -12.5 %CHF / USD -10.9 % -21.4 % -20.2 %CHF / JPY -1.7 % -11.4 % -11.9 % Differencein CHF / CER -9.1 %pt -15.2 %pt -15.7 %pt growth 1.2% -0.1% 0.3% Sales CER growth growth CHF 2011 growth vs. 2010 -9.2% -14.9% -14.5% Q1 Q2 Q3 Q4CER = Constant Exchange Rates (average full year 2010) 140
    • Group sales YTD September 2011Net fx impact of CHF -4.8 bn or -13%p -1% +6% 0% -13% +172 -251 +423 -4,807 -4,635 Pharma Diagnostics Group Fx 1 Group Division Division CHF1 avg December 2010 to avg YTD September 11 fx local absolute values at avg 2010 fx 141CER = Constant Exchange Rates (average full year 2010)
    • We Innovate Healthcare 142